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ABSTRACT 
Critically ill patients and patients undergoing cardiac surgery often experience hyperglycemia, 
hypoglycemia and glycemic variability (fluctuating blood glucose concentrations), all of which have 
been associated with adverse outcomes. Glycemic control aimed at avoiding both hyper- and 
hypoglycemia as well as at minimizing glycemic variability has been shown to be beneficial in these 
patients. In order to enable glycemic control, a safe and reliable glucose monitoring system is 
required. Additionally, monitoring of lactate is beneficial since an elevated lactate level may serve as a 
warning signal, and the knowledge of lactate concentration is necessary to guide lactate-reducing 
treatment, which has been shown to improve outcome in critically ill patients.   
Intravascular microdialysis is a technique that can monitor small molecules like glucose and lactate in 
the bloodstream without the need for blood sampling. This thesis aimed at developing intravascular 
microdialysis into a verified and accepted clinical method for continuous monitoring of glucose and 
lactate in patients undergoing cardiac surgery requiring postoperative treatment in the intensive care 
unit. Furthermore, another aim was to incorporate this technology into a standard procedure.  
The intravascular microdialysis method is based on a new and innovative technology, which involves 
a small compartment located between a catheter body and a covering microdialysis membrane. By 
perfusing this compartment, a dialysate fluid is produced wherein the concentrations of glucose and 
lactate are theoretically equal to those in the surrounding tissue, i.e. the bloodstream as the catheter is 
placed in a central vein. In Study I, the intravascular microdialysis concept was applied to a single-
lumen catheter. The dialysate fluid was collected and intermittently analyzed in a separate dialysate 
analyzer for glucose and lactate concentrations and compared to blood samples. This study verified 
the microdialysis concept as an efficient clinical method for measuring blood glucose and lactate 
levels. In Study II, the outlet of the compartment of the microdialysis catheter was directly connected 
to a recently developed sensor, continuously analyzing glucose and lactate concentrations of the 
dialysate fluid. The continuous microdialysis catheter-sensor system was shown to be very accurate in 
monitoring blood glucose, with a lag time of only a few minutes in the clinical setting. The technique 
was improved in Study III, in which the microdialysis membrane was integrated in a standard central 
venous catheter, which is routinely applied in patients subjected to cardiac surgery. The results further 
demonstrated the accuracy and reliability of the microdialysis system. The data on lactate from 
Studies II and III were processed in Study IV, which demonstrated that the microdialysis system was 
also accurate and efficient in monitoring blood lactate. In Study V, the accuracy and responsiveness of 
the microdialysis system were confirmed in an animal model during extreme hypoglycemic conditions 
and rapid blood glucose oscillations, as well as during infusion of a solution with a high glucose 
concentration via the catheter. Finally in Study VI, the microdialysis system was compared to a 
certified and clinically verified continuous glucose monitoring system placed subcutaneously. The 
microdialysis system was found to be superior in terms of accuracy and met the clinical standards in 
terms of safety in the intensive care unit, while the subcutaneous system failed in this respect.  
This thesis demonstrates that intravascular microdialysis is a safe and accurate method for 
continuous monitoring of glucose and lactate in patients undergoing cardiac surgery, and is superior to 
a subcutaneous system in this specific setting. Based on the results of the included studies, a safe, 
reliable and certified standard procedure was developed for use in critically ill patients for the 
pertinent control of blood glucose and lactate for early detection of metabolic derangement.      
SAMMANFATTNING 
Svårt sjuka patienter och patienter som hjärtopereras drabbas ofta av hyperglykemi, hypoglykemi och 
glykemisk variabilitet (fluktuerande blodglukoskoncentrationer), som alla har associerats till 
komplikationer. Glykemisk kontroll syftar till att undvika både hyper- och hypoglykemi såväl som att 
minimera glykemisk variabilitet, och har visat sig förbättra resultaten för dessa patienter. För att 
möjliggöra glykemisk kontroll krävs ett säkert och exakt system för monitorering av blodglukos. 
Monitorering av laktat har också visat sig vara värdefullt då ett förhöjt laktatvärde kan ses som en 
varningssignal. Vetskapen om laktatvärdet är nödvändig för att styra intensivvårdsbehandling som 
syftar till att minska laktatnivån, vilket kan leda till förbättrade resultat för dessa svårt sjuka patienter.  
Intravaskulär mikrodialys är en teknik som kan monitorera små molekyler, såsom glukos och laktat, i 
blodet utan blodprovstagning. Denna avhandling har syftat till att utveckla intravaskulär mikrodialys 
till en verifierad och accepterad klinisk metod för kontinuerlig monitorering av både glukos och laktat 
hos patienter som genomgår hjärtkirurgi, och som kräver postoperativ behandling på 
intensivvårdsavdelning. Vidare var syftet att införliva tekniken i ett standardförfarande. 
Intravaskulär mikrodialys är baserat på en ny och innovativ teknik, där grunden utgörs av ett mindre 
spatium lokaliserat mellan en kateterkropp och ett omgivande mikrodialysmembran. Genom att 
perfundera detta spatium produceras en dialysat-vätska, som teoretiskt kommer att innehålla samma 
koncentrationer av glukos och laktat som i omgivande vävnad, vilket i detta fall är blodbanan då 
katetern placeras centralvenöst. I Studie I applicerades det nya intravaskulära mikrodialyssystemet i en 
singel-lumen kateter. Dialysat-vätskan samlades upp och analyserades intermittent avseende glukos- 
och laktatkoncentration i en separat dialysat-analysator. Denna studie verifierade mikrodialyssystemet 
som en effektiv och noggrann metod för att kliniskt mäta blodglukos och laktat. I Studie II anslöts 
utloppet från mikrodialyskatetern till en nyutvecklad sensor, som kontinuerligt analyserade glukos- 
och laktatkoncentrationerna i dialysat-vätskan. Det kontinuerliga mikrodialyskateter-sensorsystemet 
visade sig vara mycket noggrant och exakt avseende mätning av glukos med en kort tidsförskjutning 
på bara ett par minuter. Tekniken utvecklades ytterligare i Studie III, då mikrodialysmembranet 
integrerades i en trippel-lumen centralvenöskateter, ett standardförfarande för alla patienter som 
hjärtopereras, vilket exkluderar införandet av en separat mikrodialyskateter. Resultaten bekräftade 
mikrodialyssystemets säkerhet och noggrannhet. Laktatdata ifrån Studierna II och III analyserades i 
Studie IV, och resultaten visade att mikrodialyssystemet var mycket noggrant även avseende mätning 
av laktat. I Studie V bekräftades effektiviteten och noggrannheten hos mikrodialyssystemet för 
glukosmonitorering i en djurmodell under extrema hypoglykemiska tillstånd, liksom vid snabba 
blodsockersvängningar, samt vid hastig tillförsel av en infusion med hög glukoskoncentration via 
katetern. Slutligen, i Studie VI jämfördes det intravaskulära mikrodialyssystemet med ett tidigare 
kliniskt verifierat kontinuerligt monitoreringssystem som mäter glukos i subkutan vävnad. Denna 
studie visade att mikrodialyssystemet var mer exakt vid mätning av glukos, samt uppfyllde de kliniska 
krav gällande säkerhet på en intesivvårdsavdelning, vilket inte det subkutana systemet gjorde. 
Denna avhandling visar att intravaskulär mikrodialys är en säker och effektiv metod för kontinuerlig 
mätning av glukos och laktat hos patienter som hjärtopereras, och är överlägsen ett subkutant 
monitoreringssystem i denna specifika miljö. Baserat på resultaten ifrån dessa studier har en säker, 
tillförlitlig, och kliniskt verifierad standardprocedur utvecklats för kontroll av blodglukos och laktat 
hos svårt sjuka patienter för tidig upptäckt av en metabol störning.  
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1 INTRODUCTION 
Intravascular microdialysis is a novel technique that provides continuous monitoring of small 
molecules in the bloodstream without the need for blood sampling, using a microdialysis 
catheter placed in a central vein.  
This thesis focuses on the development of the intravascular microdialysis method as a 
procedure for continuous monitoring of blood glucose and lactate in patients undergoing 
cardiac surgery. The six studies included in this thesis all explore the accuracy, safety, and 
potential clinical use of intravascular microdialysis from various perspectives. In the first 
study, intravascular microdialysis was used for monitoring of blood glucose and lactate with 
intermittent analysis in a special separate dialysate fluid analyzer. The development of a 
sensor that could be connected to the microdialysis catheter provided a possibility that 
enabled continuous glucose monitoring (CGM), which was evaluated in the second and third 
studies. Two different catheters were used, a separate microdialysis catheter (Study II) and a 
central venous catheter (CVC) with integrated microdialysis membrane (Study III). The 
fourth study assessed intravascular microdialysis for continuous lactate monitoring. As there 
were no hypoglycemic events in the second and third studies, a fifth study was performed 
using an animal model to evaluate the accuracy of CGM in hypoglycemia and in rapidly 
fluctuating blood glucose concentrations, and to assess possible interactions during glucose 
administration via the microdialysis catheter. In the sixth study, the intravascular 
microdialysis system was compared to a less invasive subcutaneous CGM system.  
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2 BACKGROUND 
2.1 MICRODIALYSIS 
2.1.1 History of microdialysis 
Microdialysis is an in vivo sampling technique first described in 1966 by Bito et al., who used 
a static dialysate sac implanted in brain tissue in dogs to measure amino acids and 
electrolytes.1 In 1972, Delgado et al. developed the “dialytrode”, the first basic microdialysis 
catheter with a semi-permeable membrane, and used it for long-term intracerebral perfusion 
in awake monkeys.2 In 1974, the technique was further improved by Ungerstedt and Pycock, 
who succeeded in measuring dopamine levels in brain tissue of rats3. Microdialysis has since 
then been used to monitor various molecules in many different tissues. With the development 
of a microdialysis membrane that can be positioned inside a blood vessel, monitoring of 
small molecules in the bloodstream without the need for blood sampling has become 
possible. Intravascular microdialysis has been shown to be useful for blood glucose and 
lactate monitoring in order to detect myocardial ischemia in patients undergoing cardiac 
surgery.4  
2.1.2 Basic principle of microdialysis 
The basic principle of microdialysis is to constantly perfuse a “tube” with a dialysate fluid. 
The tube is a microdialysis catheter that carries a specially designed semi-permeable 
membrane. Small molecules diffuse through the membrane, creating equilibrium. Hence, the 
dialysate fluid has the same concentration of permeable molecules as the site where the 
membrane is placed,5 mimicking the function of a capillary. The microdialysis technique thus 
requires a catheter with a microdialysis membrane, dialysate fluid that is pumped through the 
system, and a device for analyzing the dialysate fluid for the molecules of interest (see figure 
1).  
The studies included in this thesis have used a specially designed microdialysis membrane 
that can be placed inside a blood vessel. This enables continuous monitoring of small 
molecules in the bloodstream without blood sampling. In this thesis, intravascular 
microdialysis has been used for monitoring of blood glucose and lactate in a central vein.   
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Figure 1. A scheamtic illustation of the intravascular microdialysis system. The microdialysis membrane is 
located on a catheter positioned inside a central vein. Small molecules diffuse through the membrane, resulting 
in the same concentration of glucose and lactate in the dialysate fluid (pumped through the system by a special 
pump) as in the bloodstream. The dialysate fluid can then be analyzed for glucose and lactate concentrations.  
 
2.1.3 Factors affecting the microdialysis technique 
Recovery is a term describing the amount of monitored molecule found in the dialysate fluid. 
Absolute recovery is the amount of this specific molecule during a certain time period, and 
relative recovery is the concentration of the monitored molecule in the dialysate fluid 
expressed as a percentage of the real concentration in the studied tissue, which in the case of 
intravascular microdialysis is the bloodstream. The recovery is affected by the perfusion rate: 
if the perfusion rate decreases, the relative recovery increases. The surface area of the 
microdialysis membrane further affects the recovery, as these two factors are directly 
proportional to each other. A larger surface membrane area will result in higher recovery. 
Adjusting the microdialysis membrane area and the perfusion rate are two ways of 
influencing the recovery. 
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Liquid permeability is an attribute of the microdialysis membrane that describes its 
permeability. It is determined by measuring the volume of fluid that passes through a pre-
defined surface area of the membrane at a certain pressure in a specific time, and is expressed 
in cm/bar*s.  
2.2 GLUCOSE AND LACTATE METABOLISM 
2.2.1  Glucose 
The blood glucose concentration is tightly regulated by several different cellular events, 
controlled by various hormones. Elevated blood glucose concentrations increase the release 
of insulin, a blood glucose-lowering hormone. Insulin acts by increasing glucose uptake in 
skeletal muscle tissue and suppressing gluconeogenesis. After glucose is taken up by a cell, it 
can either be used to provide energy via glycolysis in the cytoplasm, or stored as glycogen. 
When the blood glucose level decreases, counter-regulatory hormones (glucagon, 
epinephrine, cortisol, and growth hormone) counteract the action of insulin and stimulate the 
production of glucose by increasing hepatic gluconeogenesis and glycogenolysis (breakdown 
of glycogen into glucose). Stress increases the levels of these counter-regulatory hormones, 
leading to increased blood glucose concentration. 
Glucose is metabolized via glycolysis to generate pyruvate, NADH, and 2 molecules of ATP 
(figure 2). Pyruvate may be disposed of either aerobically or anaerobically, depending on the 
tissue oxygen state. The major fate of pyruvate under aerobic conditions is transport into the 
mitochondria, where it is decarboxylated by pyruvate dehydrogenase (PDH) into acetyl-CoA. 
Metabolism of free fatty acids (FFAs) via β-oxidation is another source of acetyl-CoA. 
Acetyl-CoA enters the citric acid cycle to produce more ATP, NADH and FADH2 along with 
byproducts such as CO2, and H2O. The electron-transport chain then oxidizes the produced 
NADH and FADH2 for additional ATP synthesis through oxidative phosphorylation.  
Under anaerobic conditions, inhibition of oxidative phosphorylation results in accumulation 
of NADH, which in turn inhibits the citric acid cycle. Pyruvate is then converted into lactate 
by the enzyme lactate dehydrogenase (LDH) to regenerate NAD+ to allow the glycolysis to 
continue. Lactate may then either be transported from the cell and be used as a substrate for 
hepatic gluconeogenesis, or may be converted back into pyruvate. If blood circulation is 
decreased and washout of metabolites is reduced, accumulation of lactate occurs.  
2.2.2 Lactate 
Lactate is produced from pyruvate by LDH, which is the major fate for glucose metabolism 
in an anaerobic setting. Lactate is also produced in exercising skeletal muscle, if NADH 
production exceeds the oxidative capacity. An increased NADH/NAD+ ratio favors the 
reduction of pyruvate to lactate. In well-oxygenated skeletal muscle, heart muscle and brain 
cells during normal conditions, lactate is oxidized back to pyruvate, which is then converted 
into acetyl-CoA and used as fuel in the citric acid cycle. Lactate may also be converted back 
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to glucose via gluconeogenesis in the liver (figure 2) and subsequently released back into the 
circulation, a process called the Cori cycle.6    
 
 
Figure 2. Overview of the metabolism of glucose and lactate. 
FFA – free fatty acids, LDH – lactate dehydrogenase, PDH – pyruvate dehydrogenase, PFK – 
phosphofructokinase, NAD – nicotinamide adenine dinucleotide.  
 
As the rate of glycolysis increases during exercise in order to provide more energy, the 
produced pyruvate cannot be metabolized via oxidative phosphorylation completely, resulting 
in its accumulation and conversion into lactate. Thus, lactate serves as an important 
metabolite allowing glycolysis to continue in the environment of increased energy demand.  
Lactate has traditionally been considered a waste product of glycolysis during hypoxia, and 
hyperlactatemia regarded as a sign of tissue hypoperfusion due to anaerobic metabolism.7 
This hypoxia-induced generation of lactate is presently believed to explain an elevated lactate 
level only partially, as there is now evidence that lactate is also produced during aerobic 
conditions.8 Thus, stimulation of glycolysis increases the blood lactate concentration during 
normoxia as well. Presently, lactate is increasingly being regarded as an important molecule 
in numerous metabolic processes and as a transportable fuel for metabolism.9  
It should also be noted that an elevated blood lactate level may result from both increased 
lactate production and decreased lactate clearance. Lactate clearance is mainly performed in 
the liver and is thus dependent on tissue perfusion and liver function. Lactate clearance has 
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further been shown to be impaired in patients undergoing cardiac surgery involving 
cardiopulmonary bypass (CPB), possibly owing to a mild liver dysfunction.10   
2.3 BLOOD GLUCOSE IN CRITICAL ILLNESS  
The metabolism of blood glucose in critical illness is complex. Critically ill patients may 
develop hyper- and hypoglycemia, as well as large fluctuations in blood glucose 
concentration (glycemic variability, GV), which have all been associated with adverse 
outcomes. Glycemic control (GC) in the setting of an intensive care unit (ICU) is important, 
as it has been shown to reduce both mortality and morbidity. In order to achieve adequate 
GC, it is important that blood glucose monitoring is both correct and practicable. 
2.3.1 Blood glucose monitoring in critical illness 
How and when glucose is monitored in critically ill patients is of great importance for 
achieving GC. Glucose can be monitored using several different techniques, ranging from 
infrared spectroscopy to more manageable enzymatic methods, which most routine analysis 
methods, including those employed in hospital laboratories, point-of-care (POC) glucometers, 
and blood gas analyzers, are often based on. Three different enzymatic methods may be used 
for measuring blood glucose: glucose oxidase (GO), glucose dehydrogenase, and 
hexokinase.11 The most common is the GO method, which is summarized in figure 3.  
 
 
Figure 3. The details of the glucose oxidase method.  
C –chromogen, GO – glucose oxidase, H2O2 – hydrogen peroxide.   
 
The gold standard of blood glucose analysis is to measure the plasma glucose concentration 
in the hospital laboratory, often using the GO method described above. Plasma glucose 
concentration varies with hematocrit level, and it is approximately 11% higher than that in 
whole blood because of the large fraction of red blood cells.12  
Sending blood samples to the hospital laboratory is often too time consuming for use in 
critically ill patients, necessitating a faster method that can be used in the ICU. A commonly 
used approach for measuring blood glucose in the ICU is to intermittently obtain arterial 
1)  Glucose oxidase catalyzes the reaction:
Glucose + H2O + O2 à Gluconic acid + H2O2

2) H2O2 is quantified and used as an estimate for the glucose 
concentration using either:
-  A peroxidase reaction of a chromogen (C) resulting in a color change:
-  H2O2 + Cred à H2O + Cox
-  An electrode measuring a generated current:
-  H2O2 à 2H+ + O2 + 2e- 
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blood samples and analyze these in a blood gas analyzer, which often also uses the GO 
method. Arterial blood gas analysis has been shown to be accurate when used in the ICU as 
compared to plasma glucose analysis by the hospital laboratory,13, 14 and it is generally more 
accurate than POC devices using test strips.15 Most POC glucose monitoring systems have 
not been developed for use in the ICU setting and are not applicable,16, 17 especially if 
capillary blood samples are used.14, 18 Analysis of capillary blood samples in hypotensive 
patients with decreased peripheral circulation is not the optimal approach.19 
There are several factors that may affect the glucose monitoring accuracy of POC devices, the 
most important being the hematocrit level. Hematocrit is the fraction of red blood cells in 
whole blood, and as the glucose concentration of plasma and red blood cells differ, alterations 
in hematocrit will affect the result of measuring glucose in whole blood. Usually, an increase 
in hematocrit will cause a decrease in glucose measurement.11 Another factor that may affect 
measurements of glucometers using the GO method is treatment with oxygen. In highly 
oxygenated blood or during hypoxia, this may result in a false glucose reading.20  
Blood glucose may be measured in plasma, arterial, venous, or capillary blood, and interstitial 
fluid. Glucose concentrations in arterial and capillary blood are almost identical, whereas 
glucose concentration in venous blood is usually a fraction of millimoles per liter lower. 
Glucose molecules diffuse from capillaries into interstitial fluid passively, and therefore the 
glucose concentration in this compartment depends on blood flow and vascular permeability. 
Furthermore, the metabolic state of the subcutaneous cells affects the glucose concentration 
in interstitial fluid. It is plausible to assume that many of these factors are affected by critical 
illness.21  
2.3.1.1 Continuous glucose monitoring 
Several CGM systems currently exist for use in critically ill patients. These systems have 
been shown to reduce the workload of ICU-nurses.22, 23 Most CGM devices used in the ICU 
setting use the enzymatic GO method for glucose analysis. Two other existing techniques are 
mid-infrared spectroscopy and a fluorescence-based method. Mid-infrared spectroscopy 
detects glucose absorption using different wavelength filters, and the fluorescence technique 
uses chemical fluorescence to measure glucose concentration and requires a light source.   
CGM systems using subcutaneous sensors were originally developed for use in stable out-
clinic patients with diabetes and are currently a well-accepted and accurate monitoring 
method in such patients.24 Several studies have evaluated these subcutaneous CGM systems 
in critically ill patients and found them to be reliable both in adults25-30 and in children31, 32 
and to aid in avoiding hypoglycemia while implementing glycemic control.33 In adult patients 
undergoing cardiac surgery, subcutaneous CGM has been shown to be safe and accurate,34 
but one study found questionable accuracy during the cardiac surgery phase and early 
postoperative period owing to false hypoglycemic readings.35 A transdermal device utilizing 
a sensor that analyzes interstitial glucose is also being developed.36 
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Impaired circulation creates a theoretical disadvantage when monitoring glucose in 
subcutaneous tissue in critically ill patients,21 which may perhaps be alleviated by improved 
calibrations.29 Subcutaneous CGM has been shown to be accurate in cardiac surgery patients 
with mildly decreased microcirculation, but the sensor accuracy was affected by peripheral 
temperature.34 More invasive approaches have been developed, including the intravascular 
microdialysis technique used in this thesis. Intravascular microdialysis in a peripheral vein 
have previously been used with promising results for glucose monitoring in patients who had 
acute coronary syndromes and were admitted to a cardiac ICU,37 as well as in critically ill 
patients.38 Another more invasive CGM system is the GluCath (GluMetrics) that utilizes a 
sensor, which may be placed both in an artery and in a peripheral vein.39, 40 The sensor uses 
fluorescence to measure blood glucose optically. The same type of glucose measuring 
technique is used by the GlySure (GlySure) system that consists of a sensor placed in a 
central vein. The GlucoClear system (Edwards Lifesciences) is another intravascular device, 
consisting of a sensor placed in a peripheral vein. The sensor is covered with a GO layer and 
can measure glucose concentration when contact with blood is allowed.41   
The use of CGM in the ICU has been shown to reduce the incidence of hypoglycemia, but it 
is still uncertain if it can contribute to improved overall GC42 or reduced GV43. However, 
during a 2013 consensus-meeting dedicated to glucose control, there was general agreement 
that CGM is the future of glucose monitoring in critically ill patients.44  
2.3.2 Glycemic control in critical illness 
Why is monitoring blood glucose important in critically ill patients? Monitoring of blood 
glucose is a prerequisite for achieving GC, which has been found to be beneficial in these 
patients. The aim of GC is to avoid hyper- and hypoglycemia as well as to reduce large 
fluctuations in blood glucose concentrations, i.e. GV.  
2.3.2.1 Hyperglycemia 
Hyperglycemia is common and may be regarded as a normal response to stress aiming to 
provide the brain with nutrition (glucose) during flight-or-fight reactions. Patients with 
known diabetes mellitus (DM) and obesity are predisposed to developing hyperglycemia 
during critical illness,45 but hyperglycemia in critically ill patients develops regardless of the 
presence of DM.46, 47 The causes of this stress-induced hyperglycemia include several 
metabolic changes, such as the release of stress-hormones (e.g. cortisol and epinephrine) and 
various cytokines. This altered metabolic state leads to increased glucose production and 
peripheral insulin resistance, resulting in hyperglycemia.48, 49 Iatrogenic causes of 
hyperglycemia may also contribute, such as administration of corticosteroids and inotropes, 
and parental nutrition. 
Several studies have demonstrated an association between hyperglycemia and adverse 
outcomes in critically ill patients,50, 51 as well as in patients admitted to general wards,52 and 
in patients undergoing cardiac surgery.53 Non-diabetic patients are affected by hyperglycemia 
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during critical illness more than are patients with known DM,47, 54-56 and patients with 
hyperglycemia preceding critical illness.57 Thus, GC prior to critical illness seems to be of 
importance. Additionally, hyperglycemia has been linked to increased mortality in patients 
with myocardial infarction,58, 59 stroke,60 and trauma.61 Glucose-lowering measures have been 
shown to improve the outcome. The DIGAMI study of 1995 found that treatment with a 
glucose-insulin infusion in patients with diabetes and myocardial infarction resulted in 
decreased mortality and morbidity.62 The observation that GC is beneficial was also made in 
critically ill patients.63  
The optimal blood glucose target range in critically ill patients still remains a matter of 
controversy. Initial studies were focused on a tight glycemic control (TGC) approach, while 
more recent studies adopted a more comprehensive approach to GC including avoiding 
hyperglycemia but not necessarily aiming for the tightest interval. A landmark study 
performed in Leuven, Belgium, by van den Berghe et al. and published in 2001, 
demonstrated a significant mortality risk reduction and improved patient outcome in mixed 
medical and surgical critically ill patients receiving intensive insulin therapy (IIT), aimed at 
TGC utilizing a narrow target blood glucose range (4.4-6.1 mmol/l). The control group, 
which underwent the conventional treatment, only received insulin if the blood glucose 
concentration exceeded 12 mmol/l, with the target glucose range of 10-11.1 mmol/l. Blood 
glucose was monitored by analyzing arterial blood samples in a blood gas analyzer at 1-4 
hour intervals. The blood glucose concentrations differed significantly between the groups, 
with the intervention group demonstrating lower blood glucose concentrations than the 
control group (5.7 ±1.1 mmol/l vs. 8.5 ±1.8 mmol/l, p<0.0001). The study showed that IIT 
significantly reduced mortality in patients admitted to the ICU for more than 5 days.64 
Although reduced morbidity has been revealed with IIT in solely medical ICU-patients, 
studies have not demonstrated the same mortality benefit,65 suggesting that IIT is more 
beneficial in surgical critically ill patients. TGC has additionally been shown to result in 
lowered economic costs.66 
Following the Leuven studies, many researchers tried to confirm the positive effects of TGC, 
but did not arrive at the same conclusions. On the contrary, no mortality benefit could be 
seen, and the incidence of hypoglycemia increased.67 Two studies were even stopped 
prematurely because of the high incidence of hypoglycemia in patients treated according to a 
TGC protocol.68, 69 
With this conflicting evidence in mind, a large multi-center study including 6022 patients was 
designed in order to answer the question of whether TGC should be implemented in critically 
ill patients, the so-called NICE-SUGAR study.70 The NICE-SUGAR study randomized its 
patients to either IIT, with the target blood glucose range of 4.5-6.0 mmol/l, or to 
conventional glucose control, with the target of 10 mmol/l or less. The results directly 
opposed those of the Leuven study, as the authors reported a significant increase in 90-day 
mortality (IIT vs. conventional treatment: 27.5% vs. 24.9%, p=0.02). Monitoring of blood 
glucose was conducted using either test-strip POC glucometers or blood gas analyzers, but 
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there was no standardization as to how often the blood glucose concentration was measured. 
With the publication of the NICE-SUGAR results, TGC in critically ill patients was widely 
criticized.  
The NICE-SUGAR study results were subsequently included in a meta-analysis of TGC vs. 
conventional GC in critically ill patients, in which no overall benefit of IIT was established.71 
The meta-analysis included 26 trials with a total of 13567 patients specifically investigating 
the effect of IIT on mortality. The authors obtained a risk ratio (RR) of 0.93 (95% CI 0.83-
1.04), thus concluding that IIT does not result in reduced mortality. There was also an 
increased incidence of hypoglycemia among patients receiving IIT. However, because of the 
significant heterogeneity between the included studies, the authors suggested that patients in 
surgical ICUs may still benefit from IIT.71 
2.3.2.2 Hypoglycemia 
All studies investigating the effect of TGC have demonstrated an increased incidence of 
hypoglycemia among patients receiving IIT. In the NICE SUGAR study, the incidence of 
hypoglycemia was 6.8% in patients in the intervention group vs. 0.5% in the control group.70 
Both mild (<4.5 mmol/l) and severe (<2.2 mmol/l) hypoglycemia have been associated with 
increased mortality in critically ill patients.72-74  
Several risk factors for developing hypoglycemia in critically ill patients have been identified: 
DM, septic shock, renal insufficiency, mechanical ventilation, severity of illness, need of 
inotropic support and treatment with IIT.73, 75 
2.3.2.3 Glycemic variability 
GV reflects how much the blood glucose concentration oscillates in an individual patient (see 
figure 4). High GV is an independent predictor of adverse outcome in critically ill patients,76-
79 as well as in patients with subarachnoid hemorrhage.80 GV is better tolerated by patients 
with DM, as it has been shown that increased GV is only associated with increased mortality 
in patients without DM.56  
Several different hypotheses may explain how GV affects patient outcome. Low GV may 
indicate better nursing care. It is also possible that patients with lower GV are healthier than 
patients with higher GV, or that GV by itself may have a detrimental effect. There are studies 
indicating that GV may lead to increased oxidative stress in patients with type 2 DM.81 It has 
been suggested that IIT may improve patient outcome by reducing GV,76 further establishing 
low GV as a therapeutic target.82  
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Figure 4. Glycemic variability illustrated by two different glucose concentration curves, with the same mean 
glucose concentration but varying variability.  
GV – glycemic variability.   
 
2.3.3 Glycemic control in cardiac surgery patients 
The effect of GC varies in different patient categories. A more positive effect has been 
demonstrated in surgical ICU-patients,71 and the benefit from GC is especially obvious in 
cardiac surgical patients.83-85  
Perioperative hyperglycemia has been associated with adverse outcomes in patients 
undergoing cardiac surgery, and found to be an independent risk factor for all complications 
including death.86-88 Hyperglycemia has further been shown to increase mortality and deep 
sternal wound infection, while treatment with continuous insulin infusions aimed at 
improving GC reduced the risk of death and infection in diabetic cardiac surgery patients.89, 90 
Postoperative hyperglycemia and high glycemic variability have also been linked to an 
increase in complications following coronary artery bypass grafting (CABG).91, 92 
Studies dedicated to improving GC during cardiac surgery have arrived at varying 
conclusions, ranging from unaffected outcome93 to a beneficial effect.89, 90, 94-96 Treating 
patients with a glucose-insulin-potassium (GIK) solution during surgery and 12 hours 
postoperatively to achieve a blood glucose level in the range of 6.9-11.1 mmol/l, significantly 
reduced the incidence of atrial fibrillation, infection-related complications, and time on 
mechanical ventilation and resulted in a shorter postoperative ICU and hospital stay in 
diabetic patients undergoing cardiac surgery. Notably, a survival benefit for GIK-treated 
patients was detectable 2 years after surgery, and these patients also had lower incidence of 
recurrent ischemia.95 A positive long-term effect of improved GC was also demonstrated in 
sub-group analysis of the cardiac surgery patients included in the original van den Berghe 
study.97   
The use of continuous insulin infusion during surgery and for the first 2 days postoperatively 
reduced mortality in diabetic CABG patients, primarily due to a decrease in cardiac-related 
deaths.98 Patients receiving insulin infusions had significantly lowered blood glucose 
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concentrations, implying that the benefit in outcome originates from improved GC. 
Furthermore, improved GC has been shown to reduce the risk of deep sternal wound 
infections.99, 100 Targeting a lower glucose threshold of <6.7 mmol/l results in an increase in 
incidences of hypoglycemia and does not provide an additional clinical benefit compared to a 
more moderate approach targeting a blood glucose interval of < 10 mmol/l.101 Thus, GC after 
cardiac surgery is important, but it should not necessarily be aimed at achieving blood 
glucose concentrations that are too low.102    
2.4 MOLECULAR ASPECTS OF GLYCEMIC CONTROL 
A question arising when discussing GC in critically ill patients is whether the effect on 
outcome depends on the achievement of normalized blood glucose concentrations, 
administration of insulin itself, or a combination of these factors. In a study investigating the 
effect of insulin infusions during and after cardiac surgery, patients receiving insulin 
infusions had significantly lowered blood glucose concentrations,98 implying that the benefit 
in outcome not only originates from the administered insulin, but also from normalized blood 
glucose concentrations. 
2.4.1 Insulin has anti-inflammatory effects 
Significantly reduced levels of acute phase proteins (C-reactive protein and mannose-binding 
lectin) were found in patients treated with IIT compared to patients subjected to conventional 
GC in a sub-group of patients included in the original van den Berghe study. This implies that 
treatment with insulin exerts an anti-inflammatory effect bedsides lowering the blood glucose 
concentration.103 IIT has further been shown to lower levels of pro-inflammatory cytokines in 
patients who have undergone a traumatic incident.104 Thus the positive effect of IIT cannot 
solely be explained by normalized blood glucose concentrations.  
2.4.2 The danger of hyperglycemia 
Vascular disease is the principal cause of death in patients with diabetes. Patients with DM 
are prone to both macro- and microvasculature complications, for example atherosclerosis, 
nephropathy and retinopathy. This has resulted in hyperglycemia being regarded as a cause of 
vascular disease.105  
There are four main hypotheses explaining how hyperglycemia may cause vascular damage: 
formation of advanced glycation end-products (AGEs) that activate the AGE-receptor, 
activation of protein kinase C, and stimulation of the polylol, and the hexosamine pathways 
(figure 5).105 All these cellular pathways are activated by hyperglycemia-induced oxidative 
stress and overproduction of superoxide anion by the mitochondrial electron transport chain. 
It is believed that hyperglycemia leads to increased superoxide anion production by 
increasing the proton gradient as a result of overproduction of electron donors, i.e. NADH 
and FADH2, generated in the citric acid cycle. The high proton gradient prolongs the lifetime 
of intermediate free radical forms of coenzyme Q (ubiquinone), which reduces oxygen to 
superoxide.106  
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Figure 5. Overview of the molecular pathways of hyperglycemia-induced vascular damage. Hyperglycemia 
leads to oxidative stress that results in activation of several molecular pathways potentially responsible for 
vascular damage. 
AGE – advanced glycation end products, ET-1 – endothelin-1, NF-κB – nuclear factor kappa beta, NO – nitric 
oxide, PAI-1 – plasminogen activator inhibitor-1, PKC – protein kinase C, RAGE – receptor for advanced 
glycation end-products, VSMC – vascular smooth muscle cell. 
 
The activation of these four cellular pathways mediates vascular damage by affecting the 
endothelium in various ways (see figure 5). In the normal endothelium, several substances are 
produced and used to control and maintain vascular function. Nitric oxide (NO) is an 
important substance produced by endothelial NO synthase and responsible for vasodilation, 
as it affects vascular smooth muscle cells (VSMC).107 NO protects from atherosclerosis by 
inhibiting the interaction between the vessel wall and platelets, VSMC migration and 
leukocyte adhesion.108, 109 Hyperglycemia decreases endothelial NO concentration, resulting 
in vasoconstriction and vascular damage.105 Not only is the hyperglycemic vascular damage 
characterized by the loss of the vasodilator effect of NO, but there is also an increased 
synthesis of vasoconstrictor substances, e.g. endothelin-1. 
Hyperglycemia further results in increased activity of the pro-inflammatory transcription 
factor nuclear factor kappa beta (NF-κB), leading to increased expression of leukocyte 
adhesion molecules and production of cytokines that mediate an inflammatory response 
within the vessel wall.110 This promotes atherosclerosis, as recruited macrophages take up 
cholesterol in the form of oxidized low-density lipoproteins by endocytosis via scavenger 
receptors, which transforms them into foam cells. The foam cells form fatty streaks that are 
characteristic of the initial stages of atherosclerosis. Hyperglycemia also affects platelet 
function, resulting in a pro-thrombotic state with increased synthesis of thrombin and 
impaired fibrinolysis due to increased levels of plasminogen activator inhibitor-1.105, 111 
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2.4.3 The danger of hypoglycemia 
Studies investigating the physiological response to hypoglycemia suggest that it not only 
serves as a marker of severity of illness, but also exerts a harmful effect by itself. The level of 
IL-6 was found to be increased in healthy adults with induced hypoglycemia, suggesting that 
hypoglycemia may increase systemic inflammation.112 An episode of hypoglycemia has also 
been shown to affect the autonomous nervous system, resulting in an inadequate sympathetic 
system response in subsequent hypoglycemia.113 
2.5 BLOOD LACTATE IN CRITICAL ILLNESS 
2.5.1 Monitoring of blood lactate 
Blood lactate is an important biomarker in critically ill patients, and its measurement may aid 
hemodynamic monitoring114 as well as be of prognostic value, as elevated lactate 
concentations have been associated with worsened outcome.115-119 Monitoring of lactate 
concentrations may thus be useful in patients admitted to the ICU.120-122 This also applies to 
patients undergoing cardiac surgery, who often develop hyperlactatemia postoperatively.123 
An elevated blood lactate level may be used to predict postoperative complications and has 
been associated with increased mortality in adults124, 125 as well as in children.126 Furthermore, 
studies have demonstrated that treatment aiming at normalizing elevated lactate levels is 
beneficial in critical illness such as septic shock.127, 128 This has created interest in more 
standardized lactate monitoring in critically ill patients, and especially in assessing the lactate 
trend via repetitive measurements over time.122, 129  
2.5.2 Control of blood lactate in critical illness 
Early goal-oriented treatment in septic patients has become the standard care, since it was 
demonstrated that this resulted in significantly improved outcome and reduced mortality.130 
The Surviving Sepsis Campaign currently recommends monitoring of CVP, MAP, and SvO2, 
as well as analyzing the initial blood lactate level, mostly for prognostic purposes. The use of 
SvO2 as a hemodynamic parameter is potentially difficult as it requires special equipment, 
which may not routinely be available, in order to implement the early goal-oriented treatment. 
Regular analysis of blood lactate levels has instead been suggested to be useful, and it has 
been shown that this approach is not inferior to SvO2 monitoring.131  
Recently, studies have investigated the effect of lactate-guided treatment in critically ill 
patients. Lactate-guided treatment is a type of treatment aimed at lowering blood lactate 
levels. This treatment has been shown to be beneficial, and it may lead to improved outcome 
both in patients admitted to an ICU132 and in patients undergoing cardiac surgery.133 Thus, a 
system continuously monitoring blood lactate in such patients may be of value. 
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3 AIMS 
The aims of this thesis were to develop intravascular microdialysis into a verified clinical 
method to be used for continuous glucose and lactate monitoring in patients undergoing 
cardiac surgery.  
Specific aims:  
I. To evaluate the method of intravascular microdialysis in order to investigate if it is 
safe and potentially useful for glucose and lactate monitoring using a separate 
microdialysis catheter and separate analysis of the dialysate fluid.  
 
II. To determine the accuracy of intravascular microdialysis when a separate 
microdialysis catheter is connected to a sensor that continuously analyzes the glucose 
concentration in the dialysate fluid. 
 
III. To verify the method of intravascular microdialysis when combing the microdialysis 
concept into a standard central venous catheter. 
 
IV. To analyze the accuracy of intravascular microdialysis when it is used for continuous 
lactate monitoring using the data from Study II and Study III. 
 
V. To investigate the performance of intravascular microdialysis during hypoglycemia, 
to determine if the accuracy is affected by glucose administration, and to test the 
responsiveness to high oscillations in blood glucose concentrations. 
 
VI. To compare two different continuous glucose monitoring systems, the intravascular 
microdialysis system and a subcutaneous system, in patients undergoing cardiac 
surgery.  
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4 MATERIALS AND METHODS 
The studies in this thesis were designed to evaluate the intravascular microdialysis technique 
for accuracy and safety, when used for monitoring of glucose and lactate both intermittently 
(in a separate analyzer) and continuously (using a special sensor). As a general approach, 
glucose and lactate values determined by the microdialysis system (test method) were paired 
with glucose and lactate values obtained with a reference method. These paired values were 
then compared to assess the accuracy. Table 1 summarizes the methodology used throughout 
the studies.  
 
  
No of 
participants 
Reference 
method 
Test 
method 
Glucose or 
lactate 
analysis 
MD-
catheter 
used 
Manner of 
dialysate 
fluid 
analysis 
Study I 10 
Art-BG/ 
Ven-BG/ 
P-Glu 
MD Both DCC 
Intermittent 
in separate 
analyzer 
Study II 50 Art-BG MD Glucose SLC Continuous 
Study III 30 Art-BG MD Glucose TLC Continuous 
Study IV 80* Art-BG MD Lactate SLC+TLC Continuous 
Study V 9** Ven-BG  MD Glucose TLC Continuous 
Study VI 26 Art-BG MD/ SC-CGM Glucose TLC Continuous 
Table 1. Methodological summary for all studies included in this thesis.  
* - Patients from Study II and Study III. ** - Animals (pigs).  
Art-BG – arterial blood gas, DCC – Dipylon cardiac catheter, MD – microdialysis, P-glu – plasma glucose, 
POC – point-of-care analysis of capillary blood, SC-CGM – subcutaneous continuous glucose monitoring,  
SLC – single lumen catheter, TLC – triple lumen catheter, Ven-BG – venous blood gas.   
 
4.1 PATIENTS 
 All included patients were adults (>18 years of age) undergoing cardiac surgery with 
cardiopulmonary bypass (CPB) at the Karolinska University Hospital, Stockholm, Sweden. 
All participants had to sign a written consent form before inclusion, after having received 
both oral and written information about the study. Exclusion criteria were ongoing infection, 
a state with high risk of blood coagulation, anatomy unsuitable for safe insertion of a CVC, or 
other ongoing diseases rendering the patient unfit for inclusion.  
  17 
No postoperative anticoagulation therapy was initiated during the first 24 hours after surgery. 
Patients that stayed in the ICU after the first 24 hours received the standard anti-thrombotic 
prophylactic therapy with low molecular weight heparin. 
4.2 STUDY TECHNIQUES 
4.2.1 Intravascular microdialysis 
The microdialysis membrane was perfused with sodium chloride at a velocity of 5 ml/min. In 
Study I, the dialysate was collected in special containers, called microvials, and analyzed 
intermittently in the separate ISCUS Clinical Microdialysis Analyzer (CMA Microdialysis 
AB, Solna, Sweden). In all other studies, the microdialysis catheter was connected to the 
Eirus (Maquet Critical Care, Solna, Sweden) intravascular microdialysis system (figure 6), 
which continuously analyzes the dialysate fluid for glucose and lactate concentrations using a 
patient-specific disposable sensor and presents these values on a monitor. The glucose and 
lactate concentrations are analyzed every minute. The system is not able to measure glucose 
levels <1.0 mmol/l. The pump for delivery of perfusion fluid to the microdialysis catheter is 
integrated into the monitor.  
 
Figure 6. The Eirus intravascular microdialysis system; consists of 1) the monitor, 2) the microdialysis catheter 
with 3) the microdialysis membrane at its distal end, and 4) the sensor that continuously analyzes the glucose 
and lactate concentrations in the dialysate fluid perfused through the system by 5) the pump. In this illustration, 
a triple-lumen catheter is demonstrated, which provides a regular central venous access function as well as the 
microdialysis membrane.  
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The sensor analyzes the glucose concentration using the GO method previously described. 
Similarly, lactate concentration is measured by using lactate oxidase. The sensor is connected 
to a sensor reader, which converts the currents from the electrodes to digital signals that are 
handled by the monitor. The monitor converts the sensor signals to concentration values and 
presents these values to the user as a trend graph and a numerical value, with a time lag of 5 
minutes, which is the time necessary to perfuse the system. 
4.2.1.1 Microdialysis catheters 
The semi-permeable microdialysis membrane is located on a specially designed catheter. 
Three different microdialysis catheters have been used throughout the studies (table 2). The 
catheters used in Study I (the Dipylon cardiac catheter – DCC) and Study II (the Eirus single 
lumen catheter – SLC) were separate microdialysis catheters with a single lumen, whereas in 
Studies III-VI the microdialysis catheter (the Eirus triple lumen catheter – TLC) had multiple 
lumens, providing central venous access as well as the microdialysis function. This technical 
development of the microdialysis catheter aims to minimize the number of catheters 
necessary, as all patients undergoing cardiac surgery are in need of central venous access both 
for blood sampling and for drug administration. The Eirus TLC has three infusion channels: 
one end hole and two side holes. The end hole is situated 20 mm from the side holes, which 
are placed 10 mm apart. All infusion channels are distal to the microdialysis membrane.  
 
Catheter Used in Study 
Lumens 
(no) 
Diameter 
(Fr) 
Length 
(cm) Manufacturer 
DCC I 1 4 67 
CMA 
Microdialysis 
AB, Solna, 
Sweden 
SLC II 1 4 30 
Dipylon 
Medical AB, 
Solna, 
Sweden 
TLC III, IV, V, VI 3 7 20 
Maquet 
Critical Care, 
Solna, 
Sweden 
Table 2. Specification of the microdialysis catheters used throughout the studies.  
DCC – Dipylon cardiac catheter, SLC – single lumen catheter, TLC – triple lumen catheter.  
 
4.2.1.2 Calibration 
The ISCUS Clinical Microdialysis Analyzer is calibrated using solutions with known glucose 
and lactate concentrations at specified time intervals supplied by the machine itself. The Eirus 
intravascular microdialysis system is calibrated every 8 hours by manually entering the 
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reference glucose and lactate concentrations. If calibration is not performed, a warning box 
will appear on the monitor notifying the user that the displayed values are not calibrated. 
4.2.2 Subcutaneous continuous glucose monitoring system 
The FreeStyle Libre (Abbott Diabetes Care Inc., Alameda, CA, USA) is a subcutaneous 
CGM (SC-CGM) system. The system consists of a small sensor (approximately 2 cm in 
diameter) that is placed subcutaneously in the upper arm and a sensor reader that scans the 
sensor within a distance of 1-4 cm, and displays the glucose value (figure 7). The sensor 
automatically analyzes the glucose concentration in the subcutaneous interstitial space every 
15 minutes, utilizing the GO method. The sensor needs to be scanned every 8 hours and is 
approved for use for up to 14 days. The sensors are pre-calibrated by the manufacturer and 
cannot be re-calibrated. The system requires a 1-hour warm-up period after the sensor is 
inserted before blood glucose can be analyzed. The sensor reader has an additional function 
as a POC glucometer, and can be used to analyze glucose in capillary blood using special 
analyzing strips that are inserted into the sensor reader.  
 
 
 
Figure 7. The FreeStyle Libre subcutaneous continuous glucose monitoring system consists of 1) the sensor-
reader and 2) the sensor.  
 
 
4.2.3 Blood gases 
Analysis of arterial and/or venous blood samples in a blood gas analyzer was used as the 
reference method to compare the glucose and lactate values obtained by microdialysis.  
The blood gas analyzer used was ABL800 FLEX (Radiometer Medical, Copenhagen, 
Denmark), which utilizes the GO method for glucose measurement.  
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4.2.4 Laboratory analyses 
In Study I, the hospital’s laboratory measured plasma glucose every 4 hours. The plasma 
glucose level was analyzed by the GO method using the Beckman Coulter DxC 8000 
instrument (Beckman Coulter Inc., Brea California, United States of America). 
4.3 STUDY PROTOCOLS 
4.3.1 Study I 
Aim: To evaluate the method of intravascular microdialysis in order to determine if it is safe 
and potentially useful for glucose and lactate monitoring using a separate microdialysis 
catheter and separate analysis of the dialysate fluid.  
Patients: Ten patients undergoing cardiac surgery with CPB between April and May 2009 
were included.  
 
Figure 8. Flow chart of Study I.  
Art-BG – arterial blood gas, ICU – intensive care unit, MD – microdialysis, P – plasma, Ven-BG – venous blood 
gas. 
 
Protocol: The DCC separate microdialysis catheter was preoperatively placed in the superior 
vena cava. Microvials were inserted in the outlet of the catheter every hour to collect 
dialysate fluid that was subsequently analyzed for glucose and lactate concentrations in the 
ISCUS Clinical Microdialysis Analyzer. Arterial and venous blood samples were obtained 
simultaneously with dialysate fluid collection, and glucose and lactate concentrations were 
measured by a blood gas analyzer. In addition, a blood sample was sent to the hospital’s 
laboratory for analysis of plasma glucose every four hours (in nine patients). Analysis of 
glucose and lactate started with the patient’s arrival in the ICU after surgery and was 
terminated after a maximum of 24 hours or upon discharge from the ICU, depending on 
which event occurred first. A flow chart is presented in figure 8.      
Evaluation: Microdialysis glucose and lactate values were paired with reference values 
obtained from arterial and venous blood gas analysis. All paired samples were then analyzed 
Patient 
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• Microdialysis 
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placed 
preoperatively
Cardiac 
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Thoracic ICU
•  Every hour: MD/
Art-BG/Ven-BG 
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Study 
termination
• ICU discharge 
or
• After 24 hours
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for accuracy. Additionally, glucose and lactate values obtained by arterial blood gas analysis 
were compared to results of venous blood gas analysis in order to determine if these two 
methods could be used interchangeably as reference methods in future studies. All data 
obtained with glucose monitoring methods were also compared to the plasma glucose levels 
determined by the hospital’s laboratory.     
4.3.2 Studies II and III 
Aim: To determine the accuracy of intravascular microdialysis when a separate microdialysis 
catheter is connected to a sensor that continuously analyzes the glucose concentration in the 
dialysate fluid (Study II) and to verify the accuracy of the method when the microdialysis 
concept is implemented in a standard CVC (Study III). 
Patients: Fifty patients undergoing cardiac surgery with CPB between March and July 2010 
(Study II) and 30 patients undergoing cardiac surgery between May and August 2011 (Study 
III) were included. 
 
Figure 9. Flow chart of Study II and Study III.  
* = In Study III, the monitoring period could be extended beyond 48 hours as the patients had the microdialysis 
catheter in place longer. Monitoring beyond 48 hours was conducted occasionally. 
Art-BG – arterial blood gas, ICU – intensive care unit, MD – microdialysis. 
 
Protocol: The microdialysis catheter (Study II: Eirus SLC, Study III: Eirus TLC) was 
preoperatively placed in the superior vena cava/right atrium and connected to the Eirus 
intravascular microdialysis system. CGM was initiated after calibration of the microdialysis 
system. Reference glucose values were determined every hour by analyzing an arterial blood 
sample in a blood gas analyzer, and the time when the blood was sampled was documented. 
Patients were monitored for up to 48 hours or until they were discharged from the ICU, 
depending on which event occurred first. A flow chart is presented in figure 9. The glucose 
values obtained by the intravascular microdialysis system were not used for guiding treatment 
with insulin. All patients routinely received 5% glucose infusion (1 ml/kg/h) in the ICU and 
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insulin infusions were used if needed, with the target blood glucose concentration range both 
during and after cardiac surgery set at 5-10 mmol/l. 
In Study III, the patients had the microdialysis catheter with CVC function in place as long as 
a central line was necessary. Thus, in some patients, the microdialysis system could be used 
for glucose analysis after the 48-hour study period. This analysis was done occasionally at 
random times in 4 patients, resulting in a total of 6 paired MD/Art-BG glucose values. The 
Eirus TLC could be used for blood sampling and drug administration in the postoperative 
period. After removal of the catheter, the microdialysis membrane was checked for potential 
blood clotting.   
Evaluation: Microdialysis glucose values were paired with reference arterial blood gas 
glucose values and analyzed for accuracy. Continuous glucose values are presented on the 
monitor with a lag time equal to the time required to perfuse the microdialysis system. This 
time lag was estimated to be 10 minutes in Study II and 5 minutes in Study III, the difference 
being caused by difference in lengths of the microdialysis catheters (see table 2). To describe 
the technical accuracy of the microdialysis system better, the microdialysis glucose values 
were adjusted for the time lag when paired with respective arterial blood gas glucose values.  
4.3.3 Study IV 
Aim: To analyze the accuracy of intravascular microdialysis when it is used for continuous 
lactate monitoring using data from Study II and Study III. 
Patients: All patients from Study II (n=50) and Study III (n=30) were included.  
Protocol: No new study was conducted; instead existing data from Study II and Study III 
were analyzed. Study protocols for Study II and Study III are outlined above.  
Evaluation: The microdialysis lactate values were paired with reference arterial blood gas 
lactate values and analyzed for accuracy. If a high lactate level (>3 mmol/l) was detected, a 
possible association with an adverse event was investigated. 
4.3.4 Study V 
Aim: To investigate the performance of intravascular microdialysis during hypoglycemia, to 
determine if the accuracy is affected by glucose administration, and to test the responsiveness 
during high oscillations in blood glucose concentrations. 
Animal model: As there were no hypoglycemic incidences in Studies I, II, or III, the 
intravascular microdialysis system was not adequately evaluated in the setting of low blood 
glucose concentrations. Thus, an animal model using pigs was developed, and set up as 
displayed in figure 10. In total, 10 pigs were used (the first pig was a pilot object used to 
establish the study protocol; corresponding data were not included in the results). The 
animals were equipped with the Eirus intravascular microdialysis system using the Eirus 
TLC, which was used for all blood sampling and drug administration.  
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Figure 10. Illustration of the animal model used in Study IV. 
 
After induction of general anesthesia, the microdialysis catheter was inserted in the superior 
vena cava, and CGM was initiated. Hypoglycemia was then induced with an insulin bolus 
dose (8 units of NovoRapid (Novo Nordisk Scandinavia AB)); this insulin administration was 
considered the beginning of the analysis period (time 0). After 30 minutes, 30 ml bolus dose 
of 30% glucose was given to reverse the hypoglycemia and at 40 minutes, glucose infusion at 
100 ml/h was initiated. At 100 min, another insulin bolus dose consisting of 8 units of 
NovoRapid was given, and CGM was conducted for another 20 minutes (see figure 11). At 
the end of the study period, the animals were sacrificed. The position of the microdialysis 
catheter was controlled post mortem. 
Arterial and venous blood samples were collected every five minutes and analyzed in a blood 
gas analyzer for glucose concentrations. The microdialysis system was calibrated once at the 
beginning of the monitoring period (before hypoglycemia was induced) using the arterial 
blood gas glucose level. 
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Figure 11. The study protocol for Study V is illustrated using a typical time course of glucose concentration. The 
different phases of the study are numbered 1-4.   
MD – microdialysis, Ven-BG – venous blood gas.  
 
Evaluation: The microdialysis glucose values were paired with reference venous blood gas 
glucose values and analyzed for accuracy. To describe the technical accuracy of the 
microdialysis system better, the microdialysis glucose values were adjusted for the time lag 
(5 minutes) when paired with respective venous blood gas glucose value. Glucose level time 
courses were plotted to evaluate the responsiveness of intravascular microdialysis during 
rapid glucose fluctuations. To further evaluate the responsiveness of the microdialysis system 
and to assess the potential influence of glucose administration, the mean absolute relative 
difference (MARD) between the different study phases was compared.  
4.3.5 Study VI 
Aim: To compare two different continuous glucose monitoring systems, the intravascular 
microdialysis system and a subcutaneous system, in patients undergoing cardiac surgery.   
Patients: Twenty-six patients undergoing cardiac surgery with CPB between October and 
December 2015 were included. 
Protocol: All patients were equipped with both the Eirus intravascular microdialysis CGM 
(MD-CGM) system and the FreeStyle Libre subcutaneous CGM (SC-CGM) system. The 
sensor of the FreeStyle Libre system was inserted the day before surgery subcutaneously in 
the left upper arm. The microdialysis catheter (Eirus TLC) was inserted in the operating room 
in the superior vena cava/right atrium after the induction of general anesthesia, and connected 
to the microdialysis monitoring system. An arterial blood sample was obtained every hour, 
and the glucose concentration was analyzed in a blood gas analyzer. A capillary blood sample 
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was analyzed using the POC function of the FreeStyle Libre sensor reader every 4 hours. The 
SC-CGM system was scanned every 4 hours. The MD-CGM system was calibrated every 8 
hours. 
Evaluation: Both the MD-CGM and the SC-CGM glucose values were paired with reference 
arterial blood gas glucose values and analyzed for accuracy. To describe the technical 
accuracy of the microdialysis system better, the microdialysis glucose values were adjusted 
for the time lag (5 minutes). The MD-CGM system provides a glucose value every minute, 
while the SC-CGM system stores the glucose value every 15 minutes. In order to match the 
arterial blood gas glucose value taken at a specific time with the correct SC-CGM glucose 
value, a glucose level time course was plotted using the SC-CGM glucose values. The SC-
CGM glucose value was then extracted from this graph. POC glucose values were also 
compared with reference arterial blood gas glucose values.   
4.4 STATISTICAL ANALYSES 
All studies included in this thesis compared different techniques of glucose and lactate 
monitoring. Glucose monitoring devices can be evaluated in different ways and for two 
different aspects of accuracy: technical and clinical. Clinical accuracy is sufficient when the 
test glucose monitoring method does not report a glucose concentration leading to a clinical 
action different from the action that would have been taken based on the reference method. 
Technical accuracy evaluates how much the values determined by the test method actually 
differ from the reference values.  
In this thesis, the glucose monitoring accuracy of the intravascular microdialysis system was 
compared to a chosen reference method using the following analyses: Bland-Altman 134, 
Clarke error grid analysis (EGA),135, 136 International Organization for Standardization (ISO) 
criteria,137 and correlation coefficients.138 Accuracy of microdialysis lactate monitoring was 
compared to a chosen reference method using Bland-Altman analysis and correlation 
coefficients. Furthermore, the MARD was calculated.  
Statistical analyses were performed using IBM SPSS Statistics, version 22 (IBM, N.Y., USA) 
in all studies, except for Study VI, in which version 23 was used. Bland-Altman and EGA 
analyses were performed using Microsoft Excel (Microsoft, W.A., USA). Overall 
associations between intravascular microdialysis and the reference method were evaluated 
using the Pearson correlation coefficient. Additionally, in Study IV, the overall association 
between microdialysis and arterial blood gas lactate concentrations was assessed based on a 
regression coefficient, which was calculated using a random coefficient mixed model in SAS 
Statistical software, version 9.3 (SAS Institute Inc., N.C., USA). A Kruskal-Wallis test was 
performed in Study V to compare the MARDs in different study phases, and in Study VI to 
compare the MARDs in different blood glucose ranges.  
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4.4.1 MARD 
MARD is often used when evaluating a test measurement method. It is calculated by the 
following formula: 
+ (Test method – Reference method) / Reference method 
A MARD <14% has been suggested to indicate a good agreement between test and reference 
methods.139 Depending on the distribution of data, it is sometimes more correct to calculate 
the median absolute relative difference instead of the MARD. In Study VI, both the median 
absolute relative difference and the MARD were employed.  
4.4.2 Bland-Altman analysis 
Bland-Altman analysis is a method commonly used in medical science to compare results of 
two different measurement methods.134 The analysis plots the difference between the test and 
reference methods against their average and may be used to calculate the mean difference and 
limits of agreement (mean difference ±1.96SD). The correctness of use of Bland-Altman 
analysis in comparative studies that include multiple paired samples per patient, as is the case 
in our studies, has been questioned. To avoid possible inaccuracies, we double-checked the 
results from the Bland-Altman analyses by using the software MedCalc Statistics, version 
12.7.5 (MedCalc Software, Ostend, Belgium) that takes this problem into account.  
4.4.3 Clarke error grid analysis 
The Clarke EGA evaluates the clinical accuracy of the test glucose monitoring method in 
comparison with the reference method by plotting paired values in five distinct zones of 
different significance (see figure 12).135, 136 Paired values in zone A are within 20% of the 
reference value and their use has no clinical implications. Values in zone B exceed 20% from 
the reference value, but their use still leads to appropriate clinical decisions. Values in zone C 
may lead to unnecessary but harmless corrections. Values in zones D and E represent 
overestimation for hypoglycemia (failure to detect) or underestimation for hyperglycemia that 
may lead to incorrect clinical actions. In short, the more paired values located in zones A and 
B, the better is the clinical accuracy of the test method. 
The EGA was originally constructed to compare intermittent glucose values, and its use in 
critically ill patients, and the correctness of this approach when utilized for analyzing 
continuous glucose data, has been questioned since it does not consider the rate at which 
blood glucose concentration is changing. Although an updated EGA for CGM devices has 
been developed, we chose to use the original EGA because our chosen reference method 
(analysis of arterial or venous blood gases) was employed intermittently.140 In addition, the 
continuous EGA is difficult to use and therefore not very popular. Because of this, it is likely 
easier to compare the results between different studies when they are analyzed with the 
original EGA. 
 
  27 
 
 
 
Figure 12. Example of the Clarke error grid for evaluation of the clinical accuracy of a test glucose monitoring 
method in comparison with a reference method. Paired values in zone A are within 20% of the reference value, 
whereas values in zone B differ by more than 20% but their use leads to the same clinical actions. The use of 
values in zone C may lead to harmless but incorrect clinical actions, while utilization of values in zones D and E 
may lead to harmful and incorrect clinical actions.  
 
 
4.4.4 International Organization for Standardization criteria 
The ISO criteria (ISO15197:2003) for glucose monitoring devices states that 95% of test 
glucose values have to be within 20% of the reference value, if the reference value is >4.1 
mmol/l, and within 0.8 mmol/l, if the reference value is <4.1 mmol/l.137 After an update in 
2013 (ISO15197:2013), the criteria require test glucose values to be within 15% of the 
reference value, if the reference value is >5.5 mmol/l, and within 0.8 mmol/l, if the reference 
value is <5.5 mmol/l.141 During a consensus meeting discussing GC in the ICU, new criteria 
for accuracy of glucose monitoring devices were suggested, requiring 98% of test glucose 
values to be within 12.5% of the reference value (or within 0.55 mmol/l for readings <5.5 
mmol/l) and the remaining 2% of test glucose values to be within 20% of the reference 
value.44 In this thesis, microdialysis glucose values have been evaluated according to the 
original ISO criteria of 2003, but as the update of 2013 arrived, this was also employed for 
the analysis of the results from Study VI.  
4.5 ETHICAL CONSIDERATIONS 
All patients provided written and oral informed consent prior to study participation after 
being given both written and oral information. All studies were approved by the Regional 
Ethics Review Committee in Stockholm, application no 2007/1268-31 with acceptance as of 
2007-12-14. The following amendments to the original ethical application have been 
accepted: 2008/742-32, 2008/1608-32, 2008/1897-32, 2009/143-32, 2009/1622-32, 
2010/0109-32, 2011/467-32, 2011/1776-32/1, 2014/1479-32, and 2015/952-32. 
 28 
In Study V, the ethical permission for the animal experiments was obtained from the 
Stockholm Regional Ethical Committee, application no N397/09 with acceptance as of 2009-
12-17. All animals received humane care in compliance with the European Convention on 
Animal Care, and the investigation conformed to the Guide of Care and Use of Laboratory 
Animals published by the US National Institute of Health (NIH Publication No. 85-23, 
revised 1985). 
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5 RESULTS 
The results from the studies included in this thesis demonstrate that intravascular 
microdialysis is a safe and accurate method for continuous monitoring of both glucose and 
lactate in critically ill patients undergoing cardiac surgery.  
5.1 PATIENTS 
Characteristics of the patients included in the studies in this thesis are outlined in table 3.  
 
  
Study I Study II Study III Study VI 
Sex (male/female) 8/2 37/11 19/11  21/3 
Age (years) 65 ±11 68 ±14 67 ±12 66 ±9  
BMI (kg/m2) 24.8 ±3.0 26.6 ±4.4 27.1 ±4.8 27.2 ±3.9  
History of diabetes (no) 3 10 11 6  
Treated with insulin 1 3 4 3  
Treated with oral anti- 
diabetics 2 7 7 3  
EuroSCORE (%) 1.23 ±0.6 6.9 ±7.3 5.1 ±4.5 1.79 ±0.8  
Surgical procedure (no)         
CABG 9 25 8 6  
Valve surgery 1 20 19 14  
Other 0 3 3 4  
Time on ventilator (h) 4.2 ±3.4 7.5 ±3 11 ±11.5 7 ±1.5  
Length of ICU stay (h) 40 ±48 60 ±169 73 ±129 29 ±20  
Length of hospital stay (days) 8.0 ±2.4 6.9 ±7.3 7.9 ±5.8 5.5 ±2  
Table 3. Characteristics of the patients included in the studies in this thesis. All values are presented either as 
numbers or mean ±SD. 
BMI – Body mass index, CABG – coronary artery bypass grafting, ICU – intensive care unit.  
 
5.2 ACCURACY OF INTERMITTENT MONITORING OF GLUCOSE AND 
LACTATE WITH MICRODIALYSIS – RESULTS FROM STUDY I 
The main finding from Study I was that the intravascular microdialysis system was found to 
be a potentially useful method for monitoring of both glucose and lactate in critically ill 
patients. Table 3 demonstrates the results of accuracy evaluation.  
Both arterial and venous blood gas glucose values were accurate when compared to plasma 
glucose values analyzed in the hospital’s laboratory. A comparison between arterial and 
venous blood gas measurements revealed low mean difference and good agreement regarding 
both glucose and lactate analysis.    
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MD/Art-
BG 
MD/Ven
-BG MD/P 
Art-
BG/P 
Ven-
BG/P 
Ven-
BG/Art-
BG 
Glucose 
     
  
No of samples 174 174 36 37 37 177 
Bland-Altman (mmol/l)        
Mean difference -0.07 -0.09 -0.19 0.27 0.29 0.02 
Limits of agreement (±2SD) 1.4 1.8 1.6 0.6 1.2 1 
MARD (%) 8.6 9.8 7.6 4.1 6.6 4.3 
EGA (%) 
     
  
Zone A 93 88 92 100 98 99 
Zones A+B 100 99 100 100 100 100 
ISO 2003 criteria met (%) 93 89 92 100 97 99 
Pearson 0.93 0.89 0.94 0.99 0.96 0.96 
Lactate             
No of samples 174 174 - - - 177 
Bland-Altman (mmol/l)       
  
Mean difference  0.33 0.24 - - - 0.09 
Limits of agreement (±2SD) 0.6 0.6 - - - 0.2 
MARD (%) 28.8 21.2 - - - 11 
Pearson 0.92 0.93 - - - 0.97 
Table 3. Results from Study I.  
Art-BG – arterial blood gas, EGA – Clarke error grid analysis, ISO – International Organization for 
Standardization criteria for glucose accuracy, MAD – mean absolute difference, MARD – mean absolute 
relative difference, MD – microdialysis, MRD – mean relative difference, P – plasma glucose, Pearson – 
Pearson correlation coefficient, Ven-BG – venous blood gas. 
 
 
5.3 ACCURACY OF CONTINUOUS GLUCOSE MONITORING WITH 
MICRODIALYSIS  
In general, the intravascular microdialysis system was shown to be useful, safe, and accurate 
for CGM in patients undergoing cardiac surgery.  
5.3.1 Accuracy in normo- and hyperglycemia – results from Study II and 
Study III 
Intravascular microdialysis was used for CGM in both Study II and Study III. Comparison of 
microdialysis glucose values with the reference method (analysis of an arterial blood gas) 
revealed good accuracy. A summary of the results is shown in table 4.  
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Study II Study III 
No of paired samples 994 607 
MD glucose values (mmol/l)     
   Mean 8.27 8.52 
   Min 4.5 4.65 
   Max 15.4 23.25 
Art-BG glucose values 
(mmol/l) 	   
   Mean 8.25 8.64 
   Min 4.8	 4.9 
   Max 14.4 22.5 
Bland-Altman analysis 
(mmol/l)     
   Mean difference 0.02 -0.12 
   Limits of agreement (±2SD) 1.1 to -1.1 1.25 to -1.5 
MARD (%) 5 5.6 
EGA (%)     
   Zone A 99 97 
   Zones A+B  100 100 
ISO 2003 criteria met (%) 99.2 97.2 
Pearson 0.92 (p<0.0001) 0.92 (p<0.0001) 
Table 4. Results from Study II and Study III. 
Values are presented either as counts or as means (range, median).   
Art-BG – arterial blood gas, EGA – Clarke error grid analysis, ISO – International Organization for 
Standardization criteria for glucose accuracy, MAD – mean absolute difference, MARD – mean absolute 
relative difference, MD – microdialysis, MRD – mean relative difference, Pearson – Pearson correlation 
coefficient. 
 
The Bland-Altman analysis demonstrated low mean difference in both Study II and Study III 
(see figure 13), and the limits of agreement were near ±1 mmol/l in both studies. EGA 
analysis revealed a high clinical accuracy, with 100% of paired values within zones A and B 
(see figure 14).  
None of the patients in Study II or Study III experienced hypoglycemia. Thus, the accuracy of 
intravascular microdialysis used for CGM in the hypoglycemic range could not be evaluated 
in these studies. The target blood glucose concentration range in the ICU is 5-10 mmol/l at 
our clinic, and the glucose levels in were within this range 88% (Study II) and 85% (Study 
III) of the time.   
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Figure 13. Bland-Altman analysis of paired microdialysis and arterial blood gas glucose values from a) Study II 
and b) Study III. The straight line represents the mean difference, and the dotted lines are the limits of agreement 
(mean difference ±1.96SD).  
Art-BG – arterial blood gas, MD – microdialysis.  
 
 
Figure 14. Clarke error grid analysis of paired microdialysis and arterial blood gas glucose values from a) 
Study II and b) Study III. All paired samples were within zones A and B. 
Art-BG – arterial blood gas, MD – microdialysis. 
 
5.3.2 Accuracy in hypoglycemia – results from Study V 
In Study V, the glucose monitoring accuracy of the intravascular microdialysis system was 
evaluated in hypoglycemia using an animal model. A total of 213 paired microdialysis and 
venous blood gas glucose values were obtained. Of these, 59.2% (n=126) were in the 
hypoglycemic range (<4.1 mmol/l). The mean microdialysis glucose value was 3.89 mmol/l, 
and the mean arterial blood gas glucose value was 3.91 mmol/l. The lowest and highest 
microdialysis glucose values were 1.0 mmol/l (the method cannot measure glucose levels 
<1.0 mmol/l) and 8.9 mmol/l respectively, and the corresponding venous blood gas glucose 
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values were 0.4 mmol/l and 9.1 mmol/l. Bland-Altman analysis showed a low mean 
difference of 0.01 mmol/l, with limits of agreement of ±0.9 mmol/l (see figure 15).  
 
 
 
Figure 15. Bland-Altman analysis of paired microdialysis and venous blood gas glucose values from Study V. 
The straight line represents the mean difference, and the dotted lines are the limits of agreement (mean 
difference ±1.96SD). The mean difference was 0.01 mmol/l, and the limits of agreement were 0.87 to -0.89 
mmol/l.  
MD – microdialysis, Ven-BG – venous blood gas.  
 
The MARD was 11.8%. In Clarke EGA, all paired values were within zones A and B, and 
99% of them were situated in zone A (see figure 16). The ISO criteria were fulfilled, as 
97.7% of the paired values were within the reference guidelines. The Pearson correlation 
coefficient was 0.97 (p <0.0001). 
 
 
Figure 16. Clarke error grid analysis of paired microdialysis and venous blood gas glucose values from Study V. 
All paired values were within zones A and B, and 99% of them were within zone A.  
MD – microdialysis, Ven-BG – venous blood gas.  
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5.3.3 Responsiveness and influence during glucose administration – results 
from Study V 
The responsiveness of the intravascular microdialysis system during rapid blood glucose 
oscillations and the potential influence of glucose administration were also investigated in 
Study V. The system was found to be very responsive, as illustrated in figure 17, which 
presents the time course of glucose levels determined with different glucose monitoring 
methods. Figure 17 also visualizes another recurrent finding in all animals: arterial blood gas 
glucose values were consistently higher than microdialysis and venous blood gas glucose 
values during glucose administration (both for bolus dose and infusion), presumably because 
of the very high concentration of glucose administered in a central vein.  
 
 
Figure 17. The time course of glucose levels in a single animal in Study V. The Art-BG glucose concentration 
was higher than both Ven-BG and MD glucose concentrations during glucose administration. The study phases 
are outlined in figure 11.  
Art-BG – arterial blood gas, MD – microdialysis, Ven-BG – venous blood gas.  
 
Furthermore, the glucose monitoring accuracy of the microdialysis system was not influenced 
by glucose administration via the microdialysis catheter (either for bolus dose or glucose 
infusion), as there was no significant difference between the MARDs of the microdialysis and 
venous blood gas glucose values during the four different study phases (see table 5), as 
revealed by a Kruskal-Wallis test.  
 
Study phase 
Mean MD 
glucose 
(mmol/l) 
Mean Ven-
BG glucose 
(mmol/l) 
Mean 
difference 
(MD – Ven-BG 
in mmol/l) 
MARD 
(%) 
1) Insulin bolus dose  4.33 4.05 0.28 12 
2) Glucose bolus dose 3.75 3.34 0.41 20 
3) Glucose infusion 3.76 4.03 -0.27 8 
4) Insulin bolus dose 2.26 2.54 0.06 18 
Table 5. Blood glucose values during the different phases of Study V. The study phases are outlined in figure 11. 
No significant difference was found between the MARDs of the different phases.  
MARD – mean absolute relative difference, MD – microdialysis, Ven-BG – venous blood gas.   
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5.4 ACCURACY OF CONTINUOUS LACTATE MONITORING WITH 
MICRODIALYSIS – RESULTS FROM STUDY IV 
The intravascular microdialysis system was found to be safe and accurate for continuous 
lactate monitoring in patients undergoing cardiac surgery. The microdialysis lactate values 
were paired with arterial blood gas lactate values obtained from Study II and Study III. 
Accordingly, a total of 1601 (Study II = 994 and Study III = 607) paired microdialysis-
arterial blood gas lactate values were included in analysis. 
The mean microdialysis lactate value was 1.40 mmol/l, and the mean arterial blood gas 
lactate value was 1.38 mmol/l. The lowest and highest microdialysis lactate values were 0.35 
mmol/l and 6.07 mmol/l respectively, and the corresponding arterial blood gas lactate values 
were 0.4 mmol/l and 6.7 mmol/l. Bland-Altman analysis demonstrated a low mean difference 
of 0.02 mmol/l, and the limits of agreement were ±0.4 mmol/l (see figure 18). The MARD 
was 10.3%. The regression coefficient was 0.98 (p <0.0001) and the Pearson correlation 
coefficient was 0.96 (p <0.0001).   
 
 
Figure 18. Bland-Altman analysis of paired microdialysis and arterial blood gas lactate values from Study IV. 
The straight line represents the mean difference, and the dotted lines are the limits of agreement (mean 
difference ±1.96SD). The mean difference was 0.02 mmol/l, and the limits of agreement were 0.41 to -0.37 
mmol/l.  
Art-BG – arterial blood gas, MD – microdialysis. 
 
In 18 patients, a microdialysis lactate value >3.0 mmol/l was observed, and adverse events 
occurred in 7 of these patients (reoperation for bleeding (n=5), perioperative myocardial 
infarction (n=1), circulatory instability with transient visceral ischemia (n=1)). If the cut-off 
point had been set to 2.5 mmol/l, another patient who underwent reoperation for bleeding 
would have been identified, but this would have also resulted in inclusion of another 9 
patients who did not experience any complications. A cut-off point lower than 2.5 mmol/l 
would not have added more patients with adverse events. 
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5.5 COMPARISON OF INTRAVASCULAR MICRODIALYSIS AND 
SUBCUTANEOUS CGM – RESULTS FROM STUDY VI 
In the last study included in this thesis, the Eirus intravascular microdialysis CGM system 
was indirectly compared to a subcutaneous tissue CGM system, the FreeStyle Libre. 
Accuracy of both CGM systems was evaluated compared to the chosen reference method, 
analysis of arterial blood in a blood gas analyzer. Twenty-six patients were included, of 
which 24 had successful CGM with both monitoring systems. The FreeStyle Libre system 
functioned well in all patients, while the microdialysis system could not be used in two 
patients for different reasons. In one patient this was due to a late start of surgery and the fact 
that no personnel were available at that time to apply the system. In the other patient, this was 
due to a malfunction of the microdialysis catheter, most likely because of damage during 
insertion.   
All FreeStyle Libre subcutaneous sensors functioned well, and there were no problems with 
the insertion procedure. The sensor had to be replaced in one patient because of excessive 
sweating, which caused the first sensor to detach. The microdialysis system was calibrated 
every 8 hours using the reference blood glucose concentration obtained by arterial blood gas 
analysis.  
Glucose 
monitoring 
method 
Mean 
glucose 
(mmol/l) 
Min 
glucose 
(mmol/l) 
Max 
glucose 
(mmol/l) 
Art-BG 8.18 3.5 16 
MD-CGM 8.25 3.73 16.17 
SC-CGM 5.65 2.2 11.5 
Table 6. Glucose values measured by the different glucose monitoring methods used in Study VI. 
Art-BG – arterial blood gas, MD-CGM – microdialysis continuous glucose monitoring, SC-CGM – 
subcutaneous continuous glucose monitoring.  
 
The study period continued for a mean (range) of 23.7 (21-24) hours. Both CGM systems 
were removed after 24 hours in the ICU (n=19) or after the patient was discharged from the 
ICU (n=5). Mean, minimal and maximal glucose values measured by each monitoring 
method are presented in table 6. In concordance with these numbers, the SC-CGM system 
often reported lower glucose values than the reference method and the MD-CGM system. 
The results from accuracy analysis of both CGM systems are detailed in table 7.  
The MARD for individual MD-CGM systems ranged from 2.2% to 13.2%, and the MARD 
for individual SC-CGM systems ranged from 12.0% to 52.1%. The MARDs were similar in 
all glucose ranges (i.e. in, below and above the target range of 5-10 mmol/l) for the MD-
CGM system, but not for the SC-CGM system, for which the MARD improved (decreased) 
in higher reference blood glucose ranges. This difference in MARD was found to be 
significant in a Kruskal-Wallis test. 
A total of 87.9% of the reference glucose values were within the target blood glucose range in 
the ICU (5-10 mmol/l). Only 7 reference glucose values were below this range, and only 1 
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glucose value was classified as being in the hypoglycemic range (i.e. <4.1 mmol/l). That 
specific reference glucose value was 3.5 mmol/l, and the corresponding MD-CGM and SC-
CGM values were 3.7 mmol/l and 2.2 mmol/l respectively.  
 
 
MD-CGM SC-CGM 
Number of paired test-reference values 513 578 
Reference value in target range (5-10 mmol/l) 451 508 
Reference value below target range (<5 mmol/l) 7 7 
Reference value above target range (>10 mmol/l) 55 63 
Overall MARD ±SD (%) 6 ±7.9 30.5 ±12.4 
MARD ±SD in target range (5-10 mmol/l) 5.8 ±7.8 30.5 ±12.0 
MARD ±SD below target range (<5 mmol/l) 6.9 ±7.6 41.5 ±9.6 
MARD ±SD above target range (>10 mmol/l) 7.8 ±7.9 29.7 ±15 
Overall median ARD (%) 3.4 28.2 
Median ARD in target range (5-10 mmol/l) 3.3 27.3 
Median ARD below target range (<5 mmol/l) 5,6 43.9 
Median ARD above target range (>10 mmol/l) 5,2 25.6 
ISO 2003 criteria met (%) 95 18 
Table 7. Results of accuracy analysis of the Eirus intravascular microdialysis and the FreeStyle Libre 
subcutaneous CGM systems. The reference method was arterial blood gas analysis.  
ARD – absolute relative difference, CGM – continuous glucose monitoring, ISO – International Organization 
for Standardization criteria for glucose accuracy, MARD – mean absolute relative difference, MD-CGM – 
microdialysis continuous glucose monitoring, SC-CGM – subcutaneous continuous glucose monitoring, SD – 
standard deviation.  
 
The results of Bland-Altman analysis are illustrated in figure 19. The MD-CGM system had a 
low mean difference (SD) of 0.07 (0.77) mmol/l, with the upper and lower limits of 
agreement of 1.64 and -1.5 mmol/l. The SC-CGM system had a higher mean difference (SD) 
of -2.41 (1.12) mmol/l, with the upper and lower limits of agreement of -0.25 and -4.57 
mmol/l. The negative mean difference and limits of agreement of the SC-CGM system 
indicate that this system constantly measured a lower blood glucose value than the reference 
method.  
The EGA (figure 20) revealed good clinical accuracy of the MD-CGM system, with 100% of 
the paired values within zones A and B, and 95% of them within zone A. The EGA of the 
SC-CGM system revealed that 0.9% of the paired values (n=5) were within in zones C, D or 
E. 
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Figure 19. Bland-Altman analysis of a) MD-CGM vs. reference glucose values and b) SC-CGM vs. reference 
glucose values. The solid line represents the mean difference (MD-CGM: 0.07mmol/l, and SC-CGM: -2.41 
mmol/l). Dotted lines represent the limits of agreement (mean difference ±1.96SD). 
Art-BG – arterial blood gas, MD-CGM – microdialysis continuous glucose monitoring, SC-CGM – 
subcutaneous continuous glucose monitoring.   
 
 
 
 
Figure 20. Clarke error grid analysis of a) MD-CGM vs. reference glucose values and b) SC-CGM vs. reference 
glucose values.  
MD-CGM – microdialysis continuous glucose monitoring, SC-CGM – subcutaneous continuous glucose 
monitoring. 
 
The MD-CGM system met the ISO criteria of 2003. The updated criteria of 2013 were not 
met, as only 91% of the paired values satisfied the standard (the requirement is 95%). The 
SC-CGM system did not meet any ISO criteria, nor did the POC function of the FreeStyle 
Libre sensor reader. The POC function of the FreeStyle Libre sensor reader was used to 
measure blood glucose on 157 occasions. The mean (SD, range) of the POC glucose values 
was 6.92 (1.7, 2.9-13.4) mmol/l, and the mean (SD, range) of the paired reference glucose 
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values was 7.74 (1.79, 3.5-12.9) mmol/l. The MARD was 12.3%. The mean difference (SD) 
was -0.82 (0.8) mmol/l, with upper and lower limits of agreement of 0.75 and -2.39 mmol/l. 
5.6 MICRODIALYSIS FUNCTION, RELIABILITY, AND COMPLICATIONS – 
RESULTS FROM ALL STUDIES 
The Eirus intravascular microdialysis system monitored glucose and lactate without any 
complications or incidents in the 10 patients included in Study I, as well as in the animals in 
Study V. In Study II, the system malfunctioned in two patients, resulting in lack of 
microdialysis data. The reasons for malfunctions were catheter damage in the process of 
mitral valve surgery in one patient and sensor failure in another patient. In Study III, the 
microdialysis catheter was accidentally dislocated in one patient, resulting in premature 
ending of the measurements. This event was detected based on a warning signal for uncertain 
values due to high fluctuations in glucose concentration issued by the microdialysis system. 
Furthermore, data collection was paused in three patients when the system indicated sensor 
malfunction, but was successfully restarted after replacement of the sensor. No problems with 
the calibration procedure occurred, except in one patient in Study VI. As a result, reliable 
glucose values were unavailable for two hours for this patient. When calibration could be 
performed, the system functioned as usual. The reason for the difficulty with calibration 
remains unknown. All microdialysis catheters were easy to insert, but it is likely that the 
microdialysis membrane was damaged during insertion in one patient in Study VI, resulting 
in no microdialysis monitoring.  
In Study VI, the microdialysis system performed CGM without interruptions for 2 patients, 
whereas for the remaining 22 patients there were data gaps, the median number (range) of 
which was 3 (1-8). The data gaps were mostly short, with a mean duration (SD) of 13 (19) 
minutes and a median duration (range) of 10 (1-141) minutes. The 141-min data gap occurred 
when calibration problems were encountered in the patient described above.  
No complications, including no blood clotting of the microdialysis membrane, were observed 
for any of the microdialysis catheters used. In Studies I and II, the separate microdialysis 
catheter was removed after the end of the study period. In the remaining studies that used the 
Eirus TLC, the microdialysis catheter was removed when a central venous access was no 
longer necessary. As a result, some patients in Study III had the microdialysis catheter in 
place for a longer period of time (up to 10 days) than the planned follow-up period of 48 
hours. In 4 patients, microdialysis glucose values were obtained after 48 hours and paired 
with arterial blood gas glucose values, resulting in a total of 6 paired MD/Art-BG glucose 
values that were included in the accuracy analyses.  
Systematic drift with increased mean difference between calibrations was not detected in 
Study II and Study III. Moreover, longer monitoring times id not increase the mean 
difference with longer monitoring times (see figure 21 and 22). 
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Figure 21. Plots of the difference between paired microdialysis and arterial blood gas glucose values a) over 
time after calibration and b) during the entire follow-up period for Study II.  
Art-BG – arterial blood gas, MD – microdialysis. 
 
 
Figure 22. Plots of the difference between paired microdialysis and arterial blood gas glucose values a) over 
time after calibration and b) during entire follow-up period for Study III.  
Art-BG – arterial blood gas, MD – microdialysis. 
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6 DISCUSSION 
This thesis has developed and evaluated the method of intravascular microdialysis for 
continuous monitoring of glucose and lactate in critically ill patients undergoing cardiac 
surgery. The main finding is that the use of intravascular microdialysis for this purpose is safe 
and efficient. The monitoring of glucose is accurate in both hyper- and hypoglycemic 
conditions, the system is responsive to rapid oscillations in blood glucose concentrations, and 
the accuracy is not affected by glucose administration. Intravascular microdialysis was found 
to be more accurate than a less invasive subcutaneous CGM system. The use of intravascular 
microdialysis may improve metabolic control in critically ill patients.   
6.1 PERFORMANCE AND RELIABILITY OF INTRAVASCULAR 
MICRODIALYSIS 
Overall, the results from Studies I-VI demonstrate that the Eirus intravascular microdialysis 
system can be used for safe and accurate continuous glucose and lactate monitoring, which 
may improve GC in the ICU and allow early detection of elevated lactate levels. Compared to 
reference values obtained by arterial blood gas analysis (venous blood gas analysis in Study 
V), microdialysis glucose and lactate values had low mean differences and acceptable limits 
of agreement as determined by Bland-Altman analysis. The MARD was low in all studies 
(below the suggested <14%). The microdialysis system has also been evaluated by a different 
group with similar results.142 Furthermore, the accuracy of glucose monitoring was similar to 
that of other intravascular devices, such as the GluCath system39, 40 and the GlucoClear 
system.41  
All paired glucose values were in zones A and B of the Clarke EGA, indicating that no 
incorrect clinical action would have been taken if decisions had been based on the 
microdialysis values. The ISO criteria of 2003 were met in all the studies, except for Study I. 
The results of Studies II, III, V and VI were not accurate enough to satisfy the new criteria for 
glucose monitoring devices suggested by the 2013 consensus meeting, according to which 
98% of paired glucose values should be within 12.5% of the reference method (or 0.55 mmol 
if reference value <5.5 mmol/l). Only 94%, 90%, 85% and 86% of paired values met this 
condition respectively.  
All the microdialysis catheters used in the studies included in this thesis were placed in a 
central vein. In Studies I-II, the microdialysis catheter was located close to an additional CVC 
used for drug administration and blood sampling. In the remaining studies, the CVC function 
was integrated in the microdialysis catheter. No disturbances from the use of the CVC were 
noticed, probably owing to the high blood flow. This was further confirmed in Study V, in 
which glucose administration did not lead to increased differences between microdialysis 
glucose values and reference values. On the contrary, the microdialysis system was found to 
be very responsive to rapidly fluctuating blood glucose concentrations and unaffected by 
glucose administration. An important technical feature of the Eirus TLC to avoid this 
interference, is that the microdialysis membrane is located proximally to the infusion 
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openings of the CVC (through which drugs are administered), which are thus situated 
“downstreams”.  
Overall, the microdialysis system functioned well, with few failures. Microdialysis catheter 
malfunctions occurred in three patients. The catheter was accidentally damaged during mitral 
valve surgery in one patient in Study II, unintentionally dislocated after surgery in one patient 
in Study III, and was likely damaged during insertion in one patient in Study VI. The sensor 
malfunctioned in one patient in Study II and in three patients in Study III, but monitoring 
could be resumed after sensor replacement. Problems with calibration occurred in one patient 
in Study VI, resulting in lack of glucose/lactate monitoring for approximately 2 hours. When 
calibration was finally performed, the system resumed normal function. The intravascular 
microdialysis system is programmed to issue warnings when rapid and high variations in 
glucose levels are detected. Such warning signals for uncertain values were issued in all the 
above cases with complications. The resulting unreliable paired values were excluded from 
further analysis. We believe this was a well-justified decision, as the ICU staff would not rely 
on such microdialysis values. When the Eirus TLC is used, the time lag for the intravascular 
microdialysis system is approximately 5 minutes. The time lag depends on the length of the 
catheter and perfusion velocity. All the reference glucose and lactate values in Studies I-VI 
were corrected for this time lag to describe the technical accuracy of the microdialysis system 
more precisely. 
In Study V, we found that arterial blood gas glucose measurements were consistently higher 
than venous blood gas glucose and microdialysis glucose values when glucose was 
administered. This may be explained by the fact that the glucose (high concentration) was 
administered in a central vein and had not been processed by the peripheral cells, which 
resulted in a higher arterial glucose concentration. The extent of clinical implications of this 
finding in critically ill patients with ongoing glucose infusions in whom blood glucose 
concentration is only monitored using arterial blood is currently uncertain. However, in Study 
II and Study III, there was good agreement between venous blood glucose values (as 
determined by microdialysis) and arterial blood glucose values (as determined by blood gas 
analysis), and these values were not affected by glucose or other drug administration. 
Furthermore, a good agreement between arterial and venous blood glucose concentrations 
determined by blood gas analysis was demonstrated in Study I. Therefore, it is possible that 
the concentration of administered glucose in Study V exceeded the higher limit of the range 
normally used in a clinical setting. 
One of the advantages of intravascular microdialysis is that no blood sampling is required for 
continuous monitoring of glucose and lactate. Furthermore, the technical development of the 
Eirus TLC eliminates the need to use an additional CVC for central venous access, 
minimizing the number of catheters required and reducing the risk of infection. Thus, the use 
of the Eirus TLC, which includes a combination of a CVC and a microdialysis system, may 
be especially beneficial in critically ill patients requiring a CVC. Although invasiveness is 
one of the disadvantages of intravascular microdialysis, most critically ill patients require 
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central venous access. The disadvantage of invasiveness is irrelevant in such patients, as 
insertion of an intravascular microdialysis catheter provides both central venous access and 
the microdialysis function. In fact, the use of a microdialysis system may even be a better 
choice in this setting, since critically ill patients are often sedated, on mechanical ventilation, 
or otherwise incapacitated such that they are unable to convey signs of hypoglycemia, 
justifying the use of a more accurate although invasive glucose monitoring system. In 
contrast, the feasibility of intravascular microdialysis in more stable patients admitted to 
general wards, who are not in need of a CVC, may be debatable. 
It is noteworthy that no blood clotting of the microdialysis membrane was observed in any of 
the patients. This may be a consequence of the fact that all patients included in the studies 
were cardiac surgical patients, who often are prone to bleeding. Whether the microdialysis 
catheters are safe to use in other patient categories has not been studied. Furthermore, 
intravascular microdialysis system was tested under special circumstances (cardiothoracic 
surgery and the ICU) and with highly skilled nursing staff available. Therefore, it is possible 
that our findings are not generalizable to other centers. It should also be emphasized that this 
thesis has focused on the performance and safety of the intravascular microdialysis system, 
whereas the clinical outcomes of its application remain to be studied.  
Glucose levels determined with microdialysis were not used to guide treatment in the studies 
included in this thesis. As routine approach in the cardiothoracic ICU, arterial blood gas 
analysis was used to obtain blood glucose concentrations for guiding insulin treatment. In the 
patients included in Studies II, III and VI, arterial blood gas analysis was performed once 
every hour according to the study protocol, resulting in more frequent blood gas analysis than 
in usual clinical practice. The target blood glucose concentration range in the ICU is 5-10 
mmol/l, and patients’ glucose levels were within this range 88% (Study II), 85% (Study III) 
and 88% (Study VI) of the time. It can be speculated that the target blood glucose 
concentration would be maintained more accurately with CGM by intravascular 
microdialysis compared to less frequent blood gas analysis than once every hour, but this has 
not been studied.  
6.2 ASPECTS OF GLUCOSE MONITORING 
When monitoring blood glucose, it should be specified whether arterial, venous, or capillary 
blood is used.17 The plasma glucose level was measured in the hospital’s laboratory in Study 
I (the gold standard of blood glucose analysis) and compared to the glucose values obtained 
with microdialysis as well as to the values determined with arterial and venous blood gas 
analysis. Accuracy analysis revealed a good agreement and low mean difference for all 
comparisons (although the ISO criteria of 2003 were not met for the comparison of 
microdialysis and plasma glucose values). This indicated that analysis of arterial and venous 
blood in a blood gas analyzer is an adequate reference method for evaluation of the accuracy 
of glucose measurements by microdialysis. Additionally, arterial blood gas analysis has 
previously been validated against analysis in a hospital laboratory,13 and it is the 
recommended reference method when evaluating various glucose monitoring systems, if 
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plasma glucose analysis cannot be performed.44 This is often the case for ICUs, given that 
laboratory analysis is time-consuming and impractical. 
CGM is considered by many to be the future in glucose monitoring in critically ill patients. 
The devices providing CGM use various technologies and have different advantages and 
disadvantages. Generally, SC-CGM systems are minimally invasive but not as accurate as 
more invasive techniques.139 The results of Study VI suggest that the intravascular 
microdialysis system is superior to a SC-CGM system in terms of accuracy.  
6.2.1 How to evaluate and compare glucose monitoring devices 
Different CGM devices need to be validated against and compared to each other. It is 
important that the validation is standardized, as studies now use different methods, resulting 
in difficulties with comparing their results. Commonly used methods for evaluating glucose 
monitoring accuracy are calculating the MARD, using Bland-Altman analysis, Clarke EGA, 
and evaluation according to the ISO criteria. These approaches have all been used throughout 
the studies included in this thesis. It should be stated that the Clarke EGA was not developed 
for continuous glucose data analysis or for application in critically ill patients, and it has been 
criticized for inadequately reflecting rapid changes in blood glucose concentrations. An error 
grid for CGM data has been developed, but it is difficult to use and not readily available, as 
specific software is required.140 Additionally, it may be argued that error grids are generally 
too forgiving.    
There is no clear agreement on what is the acceptable accuracy for a glucose monitoring 
device used in critically ill patients. Not only point accuracy (reflecting differences between 
test glucose values and true reference glucose values) but also trend accuracy (characterizing 
rates of change in blood glucose concentration) is important. There are conventional methods 
that evaluate the point accuracy, but the best approaches to determine and evaluate trend 
accuracy still remain to be established. Point accuracy can be assessed by calculating and 
comparing the mean difference and the MARD, which are easy to perform and comprehend, 
and therefore are often used when comparing glucose monitoring devices.138 Calculating the 
median absolute relative difference, rather than the MARD, is probably more correct, since 
data are usually not normally distributed. Nevertheless, MARD is more often used in the 
literature, and therefore it is perhaps easier to interpret the results and to compare them 
between studies. In this thesis, we utilized the MARD for this reason. However, in Study VI 
we also employed the median absolute relative difference. It has been suggested that MARD 
should be <14%, and that MARD >18% indicates poor accuracy.139  
6.2.2 A comparison of intravascular microdialysis and a subcutaneous CGM 
system 
In Study VI, two different CGM systems were compared in terms of reliability and accuracy 
in patients undergoing cardiac surgery: the Eirus intravascular microdialysis system vs. the 
FreeStyle Libre subcutaneous system. Analysis of arterial blood in a blood gas analyzer was 
used as the reference method for accuracy analysis. The MD-CGM system was shown to be 
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more accurate in glucose monitoring than the SC-CGM system. The impact on glycemic 
control was not assessed, as this was not an aim in this study.  
Both systems were reliable and effective, and no instances of interference with clinical care 
were observed. The SC-CGM system measured the blood glucose concentration every 15 
minutes entirely without interruptions, and consequently there were no gaps in data. The MD-
CGM system measured the blood glucose concentration every minute, although occasionally 
interruptions occurred in 22 patients, resulting in data gaps. These data gaps were commonly 
very short, lasting only a few minutes.   
The MD-CGM system performed CGM more accurately than the SC-CGM system. The MD-
CGM system had a lower MARD, lower mean difference, and more acceptable limits of 
agreement as assessed with a Bland-Altman plot, than the SC-CGM system. Additionally, the 
MD-CGM system met the ISO criteria of 2003, whereas the SC-CGM system did not. If the 
MD-CGM system had been used for clinical guidance, no improper clinical actions would 
have been taken, as all the paired values were in the zones A and B on the Clarke error grid. 
This would not have been true for the SC-CGM system.  
The glucose monitoring accuracy of the SC-CGM system was worse than that in other studies 
using subcutaneous CGM systems in critically ill patients.143 The FreeStyle Libre system 
consistently measured lower blood glucose values than the reference method. After noticing 
the persistent underestimation of blood glucose concentration, we reached out to Abbott 
Diabetes Care Inc. to insure that the sensors were correctly pre-calibrated, which turned out to 
be the case. It is conceivable that the accuracy of the FreeStyle Libre system could be 
improved if onsite calibration (instead of factory pre-calibration) was possible.  
Impaired microcirculation has often been implied to be the reason for poor performance when 
using subcutaneous tissue monitoring devices in critically ill patients. However, no relation 
between reduced microcirculation and sensor function could be demonstrated in a recent 
study using a SC-CGM system in patients undergoing cardiac surgery.34 Furthermore, when 
the time course of glucose concentrations determined by all the glucose monitoring methods 
used in Study VI (i.e. arterial blood gas analysis, intravascular microdialysis and the 
subcutaneous FreeStyle Libre system) was plotted, it became apparent that the SC-CGM 
system followed the trend of the blood glucose concentration measured by the reference 
method. If impaired microcirculation did in fact explain why the SC-CGM system often 
reported a lower glucose value than the reference method, the glucose curve would probably 
be more static.  
The Eirus intravascular microdialysis system differs from the FreeStyle Libre system in some 
important technical details. While both enable CGM without the need of blood sampling, the 
FreeStyle Libre system is minimally invasive, and the sensor is easily inserted 
subcutaneously. The microdialysis system is more invasive and difficult to insert, as it 
requires central venous access and thus can only be inserted by someone capable of placing a 
CVC, e.g. an anesthesiologist. As a result, setting up the microdialysis system requires more 
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time and is more difficult. Another principal difference is in the rate of continuous glucose 
monitoring. The FreeStyle Libre system determines the glucose concentration every 15 
minutes. The CLSI (Clinical Laboratory Standards Institute) uses a 15-minute cut-off to 
define continuous glucose monitoring. Although, the FreeStyle Libre system satisfies this 
definition, it performs measurements less frequently than the microdialysis system (every 
minute). Additionally, the glucose value determined by the FreeStyle Libre system is only 
displayed on the sensor reader when it is turned on, while the microdialysis system 
continuously displays the glucose concentration as a numerical value and a trend graph on the 
bedside monitor, making this information more accessible. Moreover, the FreeStyle Libre 
system requires that the sensor is scanned every time the glucose concentration needs to be 
obtained, while the microdialysis system provides the glucose value/trend graph without any 
interventions from the attending staff after the system has been set up (with the exception of 
the calibration procedure every 8 hours). We believe that these technical features of the 
intravascular microdialysis system makes it more clinically useful and perhaps more intuitive 
to use as the glucose trend is always visible, facilitating the interpretation of the data. 
Additionally, following the glucose trend diminishes the need for absolute point accuracy, as 
each individual glucose value becomes less important if put in context of a trend.   
6.2.3 Which patients benefit from glycemic control? 
GC has been shown to be beneficial in surgical critically ill patients71 and patients undergoing 
cardiac surgery in particular.83, 84, 96 In the medical ICU, the benefit of GC is less clearly 
defined, as an improvement in morbidity has only been demonstrated in patients in need of 
intensive care for more than three days, and such patients are difficult to identify 
beforehand.65 
Why has the effect of GC been found to be more beneficial in surgical critically ill patients? 
One answer may be that when surgery is the cause of hyperglycemia, the time between the 
onset of increased blood glucose concentration and treatment (start of GC) is often short. This 
may be different in a medical setting, as hyperglycemia may have been present for a longer 
period of time, making the benefit from improved GC during the relatively short monitoring 
period less noticeable.144 It is also possible that surgical patients are more suitable and have 
better prerequisites for glucose monitoring, as they more frequently are in need of an arterial 
and/or central venous access line, which justifies the use of an accurate (but invasive) CGM 
system such as the intravascular microdialysis system.  
The diabetic status may also affect the outcome of GC. Hyperglycemia has been found to be 
more associated to increased mortality in non-diabetic critically ill patients, suggesting that 
patients with known DM tolerate a wider range of blood glucose.54-56 The same has been 
demonstrated regarding increased GV.55 This implies that it may be justified to individualize 
the target of GC in the ICU depending on the diabetic status.   
The Society of Thoracic Surgeons recommends that GC is aimed at achieving a blood 
glucose concentration <10 mmol/l in cardiac surgery patients.145 This recommendation is 
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based on studies demonstrating that less stringent blood glucose range (6.7-10 mmol/l) is not 
inferior to a strict range (5-6.7 mmol/l) in patients undergoing CABG.102, 146 A more moderate 
approach to GC is especially preferred in patients with known DM.101 However, the benefit 
of GC aimed at a glucose concentration  <10 mmol/l is no longer questionable.147   
6.2.3.1 Why is glycemic control beneficial during and after cardiac surgery? 
The benefits of GC in patients undergoing cardiac surgery may be explained by the 
alleviation of the negative effects of hyperglycemia on the cardiovascular system. The 
myocardium can use several substrates in order to produce energy (ATP) to power the 
contraction of the heart. During normal conditions, ATP is mostly obtained from lipolysis 
and β-oxidation of FFAs.148 In the presence of β-oxidation, the acetyl-CoA produced from 
FFAs inhibit PDH, thereby inhibiting glycolysis.149  
If ischemia (a state with decreased oxygen concentration) occurs in a non-diabetic 
myocardium, the metabolism will shift from using FFAs to using glucose. This shift is 
intended to increase the efficiency of oxygen consumption by the ischemic myocardium, 
since glucose metabolism is more oxygen-efficient than β-oxidation. Accordingly, glycolysis 
is accelerated to maintain the production of ATP, stabilizing cell integrity and function. 
However, the glucose metabolism is impaired in a diabetic patient, and there is a lack of 
insulin and/or insulin resistance. The myocardium is thus forced to continue using FFAs, at a 
cost of increasing myocardial oxygen consumption, which may worsen the damage from 
ischemia. Additionally, FFAs cannot be completely metabolized during ischemia, which 
results in their accumulation. This has been shown reduce contractility and increase incidence 
of ventricular arrhythmias.150 Insulin stimulates PDH in the mitochondria, leading to the 
conversion of pyruvate to acetyl-CoA. In the absence of insulin, pyruvate accumulates and is 
instead converted into lactate. Administration of insulin to a hyperglycemic patient may 
compensate for these metabolic events. Insulin increases cell glucose uptake and stimulates 
PDH, resulting in accelerated glycolysis151 and lowered blood glucose concentration. 
Furthermore, myocardial oxygen consumption is decreased as β-oxidation of FFAs is 
inhibited by stimulation of glycolysis.152  
6.2.4 Future directions of glucose monitoring and glycemic control 
CGM systems are now standard in many ICUs worldwide, but their impact on GC remains to 
be determined. To evaluate the clinical effect, it would be interesting to randomize patients to 
either glucose monitoring using intravascular microdialysis or to the present standard routine 
with intermittent blood gas analysis. This would allow establishing whether the quality of GC 
and time within the target blood glucose range differ between the groups.  
Many studies have focused on establishing the optimal blood glucose target range in critically 
ill patients, but this still remains a matter of controversy. For patients undergoing cardiac 
surgery, there are results indicating that a more moderate approach to GC is superior to a 
stricter control.146 What is unknown is if there is any specific time window when GC is 
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especially important, and whether GC is equally important during the perioperative and 
postoperative periods? As results from studies investigating GC in cardiac surgery patients 
have shown, GC seems to be of importance during surgery and the first 3 postoperative 
days.89  
Measuring glycated hemoglobin (HbA1c) preoperatively in patients undergoing cardiac 
surgery may aid in determining the metabolic state. Elevated HbA1c level before surgery is a 
strong predictor of mortality and morbidity in patients undergoing CABG regardless of the 
presence of DM.153 HbA1c is a form of hemoglobin used as a marker of average blood 
glucose concentration over a longer period of time (approximately 3 months). It is formed 
when hemoglobin is exposed to plasma glucose, and therefore increased if the plasma glucose 
concentration is high. Of note, a high HbA1c of 70 mmol/mol (8.6%) has been associated 
with a four-fold increase in mortality after CABG.154 It would be interesting to study whether 
elective patients with elevated HbA1c can benefit from delaying surgery until adequate 
preoperative GC is achieved. Additionally, an elevated preoperative HbA1c may serve as a 
predictor of increased perioperative insulin resistance and increased GV in the postoperative 
period, which has been associated with adverse patient outcome.92, 155 Analyzing HbA1c may 
also be of value in critically ill patients, as hyperglycemia has been associated with increased 
mortality in primarily non-diabetics and diabetic patients with good metabolic control. 
Critically ill patients with insufficiently controlled diabetes seem to tolerate hyperglycemia to 
a greater extent, and the association with adverse outcomes is not as definite. Thus, GC in 
critically ill patients may need to be individualized based on the pre-critical illness metabolic 
state, and measuring the HbA1c fraction may be useful in this assessment.57  
Insulin algorithms are an interesting development that may simplify GC in the ICU. These 
algorithms aim to standardize clinical practice and to aid in decisions regarding insulin 
administration. The majority of these systems rely on intermittent blood glucose monitoring, 
and are now often controlled using computers rather than manually.156 Further development 
of a closed-loop system that automatically administers inulin based on readings of a 
subcutaneous CGM system is an interesting improvement, which has been shown to facilitate 
GC in critically ill patients.157 In the future, it would be interesting to use the intravascular 
microdialysis system together with a computer-based insulin algorithm to determine whether 
better GC can be achieved, and if this approach has any clinical benefits. 
6.3 ASPECTS OF LACTATE MONITORING 
Intravascular microdialysis was demonstrated to be safe and accurate for continuous lactate 
monitoring in Study IV. Monitoring of blood lactate may be beneficial in critically ill patients 
since it can be of prognostic value and can be used to enable lactate-guided treatment, i.e. 
treatment aiming at lowering the lactate concentration in the blood. The microdialysis lactate 
values correlated well with the reference arterial blood gas lactate values, and the mean 
difference and the MARD were low.   
POC testing has made monitoring of lactate easier.158 There seems to be no signifi
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difference between lactate values measured in arterial and venous blood,159, 160 and this 
observation was further confirmed in Study I. It is preferable to perform lactate monitoring in 
critically ill patients by assessing the trend in lactate levels based on repeated lactate 
sampling. This may be used for predicting in-hospital mortality.121, 122 
A rise in blood lactate concentration was detected in every patient that suffered from an 
adverse event. Furthermore, there was an association between a higher rate of complications 
and a postoperative blood lactate concentration >3 mmol/l, although this was merely an 
observational finding, since Study IV was not aimed at assessing this association and the 
sample size was definitely not sufficient to correctly analyze this potential association. We 
based the theoretical cut-off value of blood lactate concentration >3 mmol/l on the results of a 
study investigating high lactate values and postoperative complications in adult cardiac 
surgery patients.125 A higher blood lactate cut-off value (3.0-3.5 mmol/l) has been shown to 
predict adverse outcomes better,115 but also a lower blood lactate cut off value (>1.5 mmol/l) 
has been demonstrated to be of prognostic use in critically ill patients.161  
Continuous lactate monitoring may be used for lactate-guided treatment in critically ill 
patients. Reducing blood lactate levels in treatment of sepsis has been shown to be as 
effective as targeting central venous oxygen saturation (SvO2).131 Achieving successful 
lactate clearance could even be more important in critically ill patients than improving SvO2, 
as improving SvO2 alone has been demonstrated to result in higher mortality than increasing 
lactate clearance alone.162  
Lactate-guided treatment in critically ill patients with hyperlactatemia has been demonstrated 
to result in improved outcome.132 In that study, lactate-guided treatment was aimed at 
reducing the blood lactate concentration by 20% per 2 hours and achieving SvO2 >70%, 
whereas in the control group blood lactate was not analyzed during the first 8 hours after 
randomization. Lactate-guided treatment resulted in administration of larger amounts of 
fluids during the intervention period (and smaller amounts during the following observation 
period), increased use of vasodilators, reduced mortality and a significantly reduced 
morbidity.132 In addition, in patients undergoing cardiac surgery, specific treatment aimed at 
reducing blood lactate levels has been shown to be beneficial.133     
In conclusion, adequate lactate monitoring used for lactate-guided treatment in critically ill 
patients can potentially reduce morbidity and mortality, although the exact underlying 
mechanism remains uncertain. It remains to be determined whether continuous lactate 
monitoring is superior to intermittent monitoring. The studies evaluating lactate-guided 
treatment have all been performed early in critical illness implying that lactate monitoring 
should be initiated as early as possible in critically ill patients. This further means that eligible 
patients should receive the Eirus TLC providing both central venous access and continuous 
lactate monitoring (if intravascular microdialysis is the method of choice for lactate 
monitoring). The invasiveness of the method is unlikely to be a major clinical problem, as 
critically ill patients usually require a central venous access anyway. The use of an 
intravascular microdialysis system in these patients will provide continuous monitoring and 
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consequently improved control of both glucose and lactate concentrations, with a possibility 
of early detection of metabolic derangement, which may result in a clinical benefit.  
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7 CONCLUSIONS 
 
I. Intravascular microdialysis can be used in critically ill patients, with good agreement 
between blood glucose and lactate concentrations determined by arterial and venous 
blood gas analyses, and dialysate glucose and lactate concentrations.  
 
II. The intravascular microdialysis system can be connected to a sensor that continously 
analyzes the glucose concentration in the dialysate fluid, which correlates well with the 
glucose concentration in the blood.  
 
III. The intravascular microdialysis system can be integrated in a central venous catheter, 
without changes in glucose monitoring accuracy. 
 
IV. Intravascular microdialysis is accurate for continuous lactate monitoring in critically ill 
patients.  
 
V. In an experimental animal model, the intravascular microdialysis system was accurate 
for continuous glucose monitoring during hypoglycemia, and the system was 
responsive to rapid fluctuations in blood glucose concentrations. The accuracy was not 
affected by glucose administration via the microdialysis catheter.  
 
VI. The Eirus intravascular microdialysis system is more accurate than the FreeStyle 
subcutaneous system for continuous glucose monitoring in patients undergoing cardiac 
surgery.  
 
The results of this thesis support the use of intravascular microdialysis as the preferred 
method for continuous glucose monitoring in critically ill patients admitted to intensive 
care units, in light of the importance of accurate glucose monitoring for adequate 
glycemic control. The intravascular microdialysis system also provides continuous 
lactate monitoring, which may further enhance the positive clinical effect. 
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